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ABSTRACT 
 
 The components contributing to cancer progression, especially the transition from 
early to invasive are unknown.  Consequently, the biological reasons are unclear as to 
why some patients diagnosed with atypia and ductal carcinoma in situ (DCIS) never 
progress into invasive breast cancer. The “one gene at a time” approach does not 
sufficiently predict progression.  To elucidate the early stage progression to invasive 
ductal cancer, expression signature of transcripts and transposable elements in 
micropunched samples of formalin-fixed, paraffin embedded (FFPE) tissue was 
conducted. A bioinformatics pipeline to analyze poor quality, short reads (>36 nts) from 
RNA-Seq data was created to compare the most common tools for alignment and 
differential expression. Most samples from patients prepared for RNA-seq analysis are 
acquired through archived FFPE tissue collections, which have low RNA quality. The 
pipeline analytics revealed that STAR alignment software outperformed others. 
Furthermore, our comparison revealed both DESeq2 and edgeR, with the estimateDisp 
function applied, both perform well when analyzing greater than 12 replicates. 
Transcriptome analysis revealed progressive diversification into known oncogenic 
pathways, a few novel biochemical pathways, in addition to antiviral and interferon 
activation. Furthermore, the transposable element (TE) signature during breast cancer 
progression at early stages indicated long terminal repeat (LTRs) as the most abundantly 
differentially expressed TEs. LTRs belong to endogenous retroviruses (ERV), a subclass 
of TEs.  The retroviral and innate immune response activity in DCIS, which indirectly 
xii 
 
corroborates the increase in ERV expression in this pre-malignant stage. Finally, to 
demonstrate the potential role of TEs in the transition from pre-malignant to malignant 
breast cancer we used pharmacological approaches to alter global TE expression and 
inhibit retrotransposition activity in control and breast cancer cell lines. It was expected 
that dysregulation of TEs be associated with increased invasiveness and growth. However, 
our results indicated that DNA methyltransferase inhibitor 5-Azacytidine (AZA) 
consistently retarded cell migration and growth. While unexpected, these findings 
corroborate recent studies that AZA may induce an interferon response in cancer via 
increased ERV expression. This body of work illustrates the importance of understanding 
bioinformatics methods used in RNA-seq analysis of common clinical samples. These 
studies suggest the potential for TEs as biomarkers for disease progression and novel 
therapeutic approach to investigate in additional model systems. 
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Chapter One: 
Breast Cancer, Transposons, and Transcriptomics 
 
1.1 Breast Cancer  
Breast cancer is a disease of the breast tissue in which cells grow and proliferate 
aberrantly. Ductal carcinoma is the most common type of breast cancer originating in the 
ducts that transport breast milk from the lobular glands to the nipples. Some less common 
breast cancers, e.g., lobular cancers, start in the glands that produce the milk () and rare 
cases start in other tissues of the breast. Ductal carcinomas become invasive upon 
escaping the basal membrane of the duct and invade the surrounding tissue.  
 
1.1.1 Statistics 
Breast cancer is one of the most common types of cancer in American women. 
Currently, 1 in 8 women and 1 in 833 men will be diagnosed with breast cancer sometime 
in their life. Approximately 20% of all breast cancers are diagnosed at pre-malignant 
stages [1]. Noteworthy, only ~one-third of patients diagnosed with a pre-malignant breast 
cancer will progress into an invasive form [2-4]. The American Cancer Society estimates 
that 266,120 women and 2,550 men will be diagnosed with invasive breast cancer in 2018 
[5]. The rate of incidence generally climbs with age. According to the CDC, in 2015 woman 
between the ages of 40 and 44 had an incident rate of 126 per 100,000 women. This rate 
increased and peaked in women between the ages of 70 and 74 at 462 per 100,000 
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women. While age is the most prominent risk factor for cancer, ethnicity, race, and sex 
also play a role in susceptibility. For example, Caucasian and African-American women 
have the highest rate of new cancers at 126 and 123 per 100,000 respectively, whereas. 
Asian/Pacific Islander, Hispanic, and Native American women had rates at 94, 93, and 71 
per 100,000 respectively [6].     
Breast cancer is the second leading cause of death in women, behind lung cancer. 
The chance a woman will die from breast cancer is 1 in 38. The earlier breast cancer is 
diagnosed, the greater chance of surviving 5 years. If the cancer is at stage 0 or I the 
chance of surviving 5 years is 100%. Stage II and III have a 5-year survival rate of 93% 
and 72%, respectively. Stage IV breast cancer has a dramatic decrease in survival rate with 
only 22% of patients surviving the next 5 years. The average survival rate for the first 5 
years after diagnosis is 90% and 83% for 10 years after diagnosis [7].   
 
1.1.2 Risk factors 
A clear majority of breast cancers develop sporadically clouting its etiology. 
However, there are well established risk factors associated with increasing your chances 
of developing breast cancer. The most common non-genetic, non-modifiable risk factors 
are age, race, early menarche, late menopause, and history of breast cancer. Non-genetic 
modifiable risk factors include income, education, insurance status, reproductive 
patterns, menopausal hormone use, tobacco use, alcohol use, fitness and nutrition. 
Genetic risks factors include mutations in one of the two BReast CAncer (BRCA) 
susceptibility genes.  
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1.1.2a Non-genetic, Non-modifiable Risk Factors  
As mentioned previously there is an increase in breast cancer incidence and 
mortality proportional to increasing age. Disease incidence begins to have a sharp incline 
starting at age 40 and peaking at age 60 throughout the world.  The median age at death 
due to breast cancer is 68 years. African American women have a median age of death at 
62 years while non-Hispanic Caucasian women’s median age of death is 69 [8] , which 
may suggest either a genetic predisposition or health disparity by ethnicity.  
Besides the significant disparity in age of death, there additional health disparities 
between non-Hispanic Caucasian women and African-American women for breast cancer 
statistics. In addition, African-American women have the highest 5-year breast cancer 
mortality rate irrespective at stage of diagnosis, indicating that early detection is not 
yielding better health outcomes. In 2012, the breast cancer death rate was 42% higher in 
African-American women than in Caucasian women [9]. Even after controlling for stage 
of disease, tumor characteristics, follow-up, uniform treatment, and other breast cancer 
risk factors African-American women were more likely to die from breast cancer [10-12]. 
Furthermore, African-American women are more likely to develop a genetically more 
aggressive type of cancer, having the largest proportion of HR-/HER2 breast cancer 
compared to other ethnicities [9, 10]. The HR-/HER2 subtype of cancer is associated with 
a poor prognosis [13, 14]. Conversely, the lowest incidence and mortality rates in the 
United States of America belong to Asian/Pacific Islander women followed closely by 
Alaskan natives, American Indians, and Hispanic women [9, 15].  The reason for lower 
breast cancer incidence in these ethnic groups is speculated to be associated with different 
reproductive patterns. Specificity, increased duration of fertility increases the risk of 
developing breast cancer [16]. For example, girls who start menstruating before the age 
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of 11, have a 20% higher breast cancer risk than girls who begin at age 13. Furthermore, 
women who began menopause at 55 years old had a 12% higher chance of breast cancer 
compared to women who began menopause at 50-54 years old [17].   
Another biological risk factor is density of breast tissue increases the risk of breast 
cancer [18]. Women with breast density greater than 50% and 26%-50% were 2.3 and 1.6 
times higher risk for breast cancer diagnosis compared to women with breast density 
between 11%-25% [19, 20]. These observation are  further convoluted because denser 
breasts are harder to diagnose from impaired mammographic detection [21].  
1.1.2b Nongenetic, Modifiable Risk Factors  
 Reproductive patterns. Women who have their first child at a younger age and 
a greater number of children have a decreased breast cancer risk. Conversely, delaying 
childbearing, having fewer children, decreased length of time breastfeeding, and 
hormonal contraceptives are linked to increased breast cancer risk [22, 23]. There is a 
50% reduced lifetime risk in women having a first child before the age of 20. There is an 
association of decreased breast cancer risk when the first child is closer to menarche [5, 
24]. Premenopausal breast cancer risk is increased by 5% for each year the first birth is 
delayed from menarche. Furthermore, each full-term pregnancy was shown to lead to a 
12% decrease in postmenopausal breast cancer risk [25]. For every year of breastfeeding 
there is a 4% reduction in a woman’s risk of breast cancer. 
Hormone Replacement Therapy. There is a higher risk correlated with 
prolonged use of post-menopausal hormones use, from starting hormone replacement 
therapy at the start of menopause, and using combined estrogen and progestin [26]. The 
risk appears to dissipate back to baseline after 5 years of discontinued use of synthetic 
hormones [27].     
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Tobacco Use. There is evidence that smoking prior to menopause will increase a 
woman’s risk of developing breast cancer. Furthermore, women who started smoking 
before their first pregnancy had a 21% higher risk of developing breast cancer. Conversely, 
some studies show that women who start smoking after menopause had a decreased risk 
of developing breast cancer, possibly due to an antiestrogenic effect of tobacco [28, 29].  
Alcohol Use. Many studies have found a dose-dependent association of alcohol 
consumption and increased breast cancer risk [30, 31]. Other studies found chronic 
alcohol consumption associated with breast cancer incidence. Further studies identified 
binge drinking associates with cancer incidence [32]. While the type of alcohol consumed 
didn’t affect the incidence rates, the majority of breast cancers associated with alcohol 
consumption are the estrogen receptor positive subtype [33-35].   
Socioeconomic Status. Socioeconomic status is more complicated risk factor 
for breast cancer. For example, women with higher socioeconomic status have 
significantly higher rates of breast cancer incidence [36-38], whereas, the 5-year survival 
rates for each stage at diagnosis are lower in patients who reside in lower socioeconomic 
areas [39]. Reduced access to routine health checkups is linked to poor outcomes for 
breast cancer. For instance, the group with the highest mortality rate include women 
without insurance or only Medicaid [40]. 
1.1.2c Genetic Risk Factors 
The most common hereditary breast and ovarian cancer is caused by genetic 
mutations in one of the two BReast CAncer (BRCA) genes, BRCA1 and BRCA2. These 
mutated genes account for 3% and 10% of all breast cancers and ovarian cancers in 
women, respectively [41]. Women, without a genetic mutation common in breast cancer, 
have a 12% chance of being diagnosed with breast cancer sometime in their lifetime. 
6 
 
However, women with a BRCA1/2 mutation have a 45-65% chance of being diagnosed 
within their lifetime [42-44]. Men who have the BRCA2 gene mutation substantially 
higher chance of a breast cancer incident. As mentioned previously, less than 1 in 1,000 
men will develop breast cancer, however men with a mutation in BRCA2 have a 50-80% 
in 1,000 chance of developing breast cancer [45-48]. The genetic causes of breast cancer 
account for 5 to 10% of the overall breast cancer cases in women, whereas in men, up to 
40% of cases are caused by a BRCA2 mutation [49]. In addition to mutations in the BRCA 
genes, there is supportive evidence the following list of genes increases the risk of breast 
cancer: ATM, BARD1, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, RAD51D, STK11, and 
TP53.  
  
1.1.3 Types and Subtypes 
Histologically, breast cancer has been categorized, broadly, into carcinoma in situ 
and invasive.  Further classification of carcinoma in situ is distinguished by anatomical 
location, ductal or lobular, known clinically as ductal carcinoma in situ (DCIS) and lobular 
carcinoma in situ (LCIS), respectively. DCIS has been further histologically subclassified 
into Comedo, Cribiform, Micropapillary, Papillary, and Solid [50]. While these 
subclassifications are a valuable histological tool, these subclassifications lack molecular 
definitions proven to be prognostically significant [51]. Invasive carcinomas have several 
different histological subtypes, as well. The most common histological subclassification 
of invasive breast cancer is infiltrating/invasive ductal carcinoma (IDC) accounting for 
70% to 80% of all invasive forms [52]. IDC has been further subclassified into well (grade 
1), moderately (grade 2), and poorly (grade 3) differentiated based on mitotic index, 
pleomorphism, glandular formation [53]. The other major subclassifications of invasive 
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breast cancer are invasive lobular, mucinous, tubular, medullary and papillary 
carcinomas. 
Clinical assessments of IDC utilize molecular markers to distinguish differences in 
prediction of overall survival. Traditional molecular classification of invasive breast 
cancer relied on markers for estrogen receptor (ER), progesterone (PR), and human 
epidermal growth factor receptor (HER2). However, through gene expression and 
immunohistochemical analysis a spectrum of molecular subtypes suggests prognostic 
status with five major subtypes. Claudin-low molecular subtype is typically triple negative 
(ER-, PR-, HER2-), associated with the worst prognosis, and a mesenchymal phenotype 
[54-56]. The basal subtype usually has a triple negative molecular profile, as well, but 
mimics basal epithelial cells, similar to normal breast myoepithelial cells, with low to no 
hormone receptor and HER2 expression and high basal membrane marker expression, 
such as keratins and EGFR [57, 58].  The basal subtype is associated with a poor prognosis 
[58, 59].  The middle of the prognostic spectrum has HER2 enriched molecular subtypes 
[58, 60, 61]. HER2 overexpression tumors are typically ER and PR negative and have 
enhanced expression of genes in the HER2 amplicon with a high rate of TP53 gene 
mutation associations [62]. The generally poor prognosis associated with the HER2 
overexpression subtype is due to the high risk of early relapse when treatment fails to 
completely eliminate the cancer [61]. Luminal breast cancers have expression profiles 
similar to the luminal epithelial component of the breast and are associated with ER 
expression and downstream activation of ER gene pathways [57]. Luminal B tumors are 
the triple positive (ER, PR, HER2) subtype when diagnosed through 
immunohistochemically, however expression profile of luminal B tumors reveal only part 
of the tumors are HER2+ [63, 64].  Luminal A tumors are the ER+, PR+, and HER2- 
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subtype and have higher expression of ER related genes but lower expression of 
proliferative genes than luminal B tumors [60, 65]. In general, the luminal tumor 
subtypes have a good prognosis and make up the majority of breast cancer tumor 
diagnoses. However, luminal B tumors have significantly worse outcomes than luminal A 
tumor subtypes [60].  
 
1.1.4 Models of Breast Cancer 
1.1.4a In Vitro  
The first breast cancer cell line was derived in the late 1950s from a mammary duct 
carcinoma [66]. Subsequently, breast cancer cell lines have become the principle models 
for clarifying apoptosis, genetic contributors, migration, proliferation, and signaling 
pathways. Currently, the most commonly used breast cancer cell line is MCF-7, which is 
positive for estrogen hormone receptor expression [67]. In general, genome and RNA 
sequencing has revealed the genetic and molecular expression profiles for the most 
common breast cancer cell lines and revealing their shared commonalities within the 
spectrum of clinical breast cancer subtypes.  Briefly, no one cell line models the full 
spectrum of breast cancer heterogeneity, however panels of cell lines encompass large 
portions of the molecular subtyping [68-71]. Thus, breast cancer cell lines are an 
appropriate experimental tool applied to derive information pertaining the specific 
subtype of breast cancer resembling to its molecular profile [72]. The popularity of breast 
cancer cell lines as a model of breast cancer is primarily for their ease of use and their 
being perceived as more “relevant” to human disease when compared to animal models. 
For example, a study showed that steroid hormone dependence is not well modelled in 
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mice and the elements that contribute to transformation in mouse and human epithelial 
cells are debatably different [73-76].   
Furthermore, cell lines can be grown as xenografts to provide more clinically 
relevant information as an in vivo model. Notably, the same cell line may adopt many 
variants between labs with distinct molecular profiles and phenotypes, which may 
account for variation when comparing published studies [77]. Another important 
consideration about breast cancer cell lines is that a majority are grown in 2D. Two-
dimensional growth is different than the in vivo breast microenvironment. Recent studies 
indicate that 3D culture more accurately recapitulates and expresses more pathways 
found in breast [78-83].  
1.1.4b In Vivo  
Research using in vivo model systems has provided improved therapeutic options 
for breast cancer, and observations of disease progression.   
Xenografts. To investigate facets of breast cancer biology using cell lines that 
more closely proximate in vivo, cell lines can be xenografted into immunocompromised 
animals, such as SCID - “severe combined immunodeficiency”- strains of mice. 
Furthermore, xenograft models allow investigation into multicellular interactions that 
recapitulate more clinically relevant observations. These facets include tumor initiation 
and growth, microenvironmental effects, and metastatic progression [84]. Albeit, 
xenograft models have many limitations. First, as mentioned previously, xenografts must 
be placed into immunocompromised animal models. The immune system has been 
implicated in tumor progression and development for early stage breast cancer and 
metastasis [85-87]. Many xenografts are generated by subcutaneous injections, which is 
not a clinically relevant microenvironment. Conversely, orthotopic transplantation of 
10 
 
cells into mouse mammary glands better approximates the human patient 
microenvironment. However, mouse and human mammary stroma have differences that 
need to be considered [88]. Xenografts in mouse models preferentially metastasize to the 
lungs and rarely grow at other common metastatic sites observed in human breast cancers 
[89]. Finally, many xenografts originate from a single breast cancer cell line, which fails 
to mimic the heterogeneity of intratumor. Recently, xenograft studies with entire panels 
of breast tumor subtype cell lines suggest potential for a suitable translational preclinical 
model in vivo [68].  Despite these limitations, xenograft models have produced many 
important insights relevant to breast cancer biology, prognosis, and treatment [90-92].  
Genetically engineered mice. The spontaneous tumor generation of 
genetically engineered mice (GEMs) into the correct tissue of interest provides great 
insight into early tumor initiating events. However, the traditional regulatory elements 
used to drive transgene expression in GEMs and the mouse microenvironment may not 
reflect clinical relevance. For instance, GEMs tumor pathology does not perfectly reflect 
the disease in humans [93, 94]. The attempt to recreate breast cancer subtypes in vivo 
has led to the generation of lineage specific promoters. To drive basal lineage oncogenic 
events keratin 14-Cre and keratin 5-Cre have been used. Whey acidic protein promoter 
(Wap)-Cre and keratin 8-Cre drivers target luminal cells for oncogenic events. To target 
ER- or ER+ luminal cells beta-lactoglobulin-Cre and Cited1-Cre are used, respectively. 
Despite these lineage specific promoters, many off-target and unexpected expression has 
confounded the interpretation of experimental results [95-98]. Regardless of 
confounding issues, genetic profiling of GEMs aligns to their relevant molecular cancer 
subtypes [99-101].  
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Furthermore, studies with GEMs representing subtypes of breast cancer has 
elucidated tumor cell of origin [102, 103].  For example, the BRCA1 deficiency tumor types 
was thought to originate from basal stem cells, however GEMs it delineated their cell type 
of origin to luminal progenitors [104, 105].  
 Despite the success of targeted therapies in breast cancer, drug resistant relapse 
remains an issue. Clinically relevant models of genetically engineered mice have been 
generated to study drug resistance, drug combination therapies, and metastasis. These 
models have elucidated putative mechanisms of drug resistance and can shutdown critical 
pathways that underlie drug resistance [106-108].  The use of GEMs in preclinical breast 
cancer trails for drug combination therapies relies heavily on design and collaboration 
between clinicians and scientists. When considered thoughtfully such studies have 
resulted in FDA approved therapeutic options [109, 110]. Although relatively few GEMs 
recapitulate clinical metastases, a few GEM studies have been instrumental in elucidating 
lymph and lung sites of breast cancer metastasis [111]. A recent study using CRISPR/Cas9 
in combination with GEMs demonstrates their potential as a model of functional 
relevance to breast cancer tumors highlighting future possibilities with GEMs [112].      
1.1.4c Characteristics During Transformation 
Despite these models have contributed significantly to understanding breast cancer 
subtypes in late stages[113], relatively little research investigates the factors underlying 
early stages of cancer transformation. There are a few hypotheses that describe the 
transformation of breast cancer subtypes from normal tissue to aggressive metastasis, 
which are mutation-of-origin, cell-of-origin, and a hybrid of both ideas [114-116].  
Briefly, genetic profiles of subsets of normal mammary epithelial cells were derived 
and compared to gene expression in breast cancer subtypes. These comparisons indicate 
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there is a high overlap of normal luminal gene expression with luminal breast cancer 
subtypes [117]. Furthermore, claudin-low expression profiles resembled metaplastic 
CD10+, epithelial-to-mesenchymal transition, and cancer stem cell profiles [118]. These 
data indicate a cell-to-lineage tumor origin. Conversely, analysis of basal-like and HER+ 
subtypes found expression profiles that were similar to luminal progenitor cells alluding 
to a mutation-of-origin model [119, 120]. Additionally, when luminal and basal mammary 
epithelial cells were isolated, transformed and implanted into immunocompromised 
humanized mice, the transformed luminal cells generated both luminal-like and basal-
like tumors and the basal transformed cells generated rare metaplastic tumors that 
resembled the claudin-low subtype [116, 121]. Currently, a hybrid model best explains 
cellular transformation within the of tumor origin. 
 In general, metastatic ductal carcinoma begins as epithelial atypical growth inside 
the breast duct surrounded by myoepithelial cells and a basement membrane. This stage 
is known as early neoplasia, or more commonly as Atypia (Figure 1.1, second panel from 
left). As further mutagenic events occur, a heterogeneous population arises filling the 
Figure 1.1 Breast Cancer Progression Top. Histological representation of ductal breast cancer 
progression. Bottom. Cartoon representation of ductal breast cancer progression. Left to right. 
Normal ductal tissue, atypical growth occurs, Ductal Carcinoma in situ, and Invasive Ductal 
Carcinoma. (Unpublished) 
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duct, which is called as ductal carcinoma in situ (DCIS) (Figure 1.1, third panel from left). 
As mentioned previously, only 1/3 of these ductal carcinomas escape the basement 
membrane resulting in invasive ductal carcinoma (IDC) (Figure 1.1).     
1.1.4d MCF10A & Derived Cell Lines 
The numerous models available for breast cancer development and metastasis 
have provided invaluable information. The MCF10A cell line is the most commonly used 
model for normal breast tissue in vitro. These cells were derived from benign fibrocystic 
diseased breast tissue that were spontaneous immortalized in culture. They have 
amplifications of the Myc gene and genomic deletions of p16 and p14ARF genes. They are 
not tumorigenic and are ER- [122]. Genomic stability studies determined that the 
MCF10A cell line is fairly stable and diploid with exception to chromosome 17 which had 
higher percentages of being instable [123]. When cultured on top of Matrigel they form 
spheroids with a hollow lumen that is covered by a basement membrane [124, 125]. 
Several cell lines have been derived from MCF10A cells by inducing transformation often 
with gene expression constructs. As a model of early transformation, MCF10A cells were 
transformed with H-ras which generated MCF10AT cell line [126, 127]. They grow on 2D 
environment, similar to the epithelial cells from which they were derived. In 3D culture 
they form multi-acinar structures [128]. These cells were xenografted into 
immunocompromised mice and generated nodules that progressed into atypia and then 
carcinoma in situ in a quarter of the mice [126, 129]. The MCF10DCIS.com cell line was 
generated from tumors that grew from the xenografted MCF10AT cell lines. Injection of 
the MCF10DCIS.com cells into SCID mice produced tumors that were composed of tightly 
packed tubular structures with central necrosis and basement membranes surrounding 
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each node intact. Later passages of the cell line that were in injected into SCID mice 
generated more aggressive and invasive tumors [130, 131].  
 
1.2 Transposable Elements (TEs) 
Transposable elements (TEs) are genetic components capable of transposing or 
replicating themselves within a host genome. Barbara McClintock discovered 
transposable elements through her work with maize. Initially distributing them into two 
categories: TEs that are autonomously transposing, containing DNA to encode the 
necessary components to reverse 
transcribe itself and non-autonomous TEs, 
which lacks the ability to reverse transcribe  
and relies parasitically upon the reverse 
transcription machinery from other 
transposons (Figure 1.2) [132]. A widely 
adopted proposed classification system for 
eukaryotic transposable elements can be 
found in a perspective paper [133]. There 
are two classes of TEs, class I are described 
as RNA mediated replication and DNA 
mediated replication is class II. Both classes have autonomous and non-autonomous 
elements (Figure 1.2).  
 
 
 
Figure 1.2. General Classification of Transposable 
Elements (TEs). (Unpublished) 
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1.2.1 Classification of Transposable Elements in Humans  
Class I TEs are often referred to as retrotransposons and include subclasses of long 
terminal repeat elements (LTRs) and non-long terminal repeat elements (non-LTRs) 
(Figure 1.3). LTR retrotransposons have many sub-classes; however, the most widely 
known and studied are divided into the following three groups; mammalian apparent LTR 
retrotransposons (MaLR), endogenous retroviruses (ERVs), and Gypsy-Ty3/Copia-Ty1 
elements.  The Copia/Ty1 group and the Gypsy/Ty3 group are distinguished by the 
 order of the three protein domains, protease (PR), reverse transcriptase (RT), and 
integrase (IN), encoded within the polymerase (pol) gene of the elements. 
Figure 1.3 Classification of Human Transposable Wlements. Elements are in hierarchical order 
starting with generalized transposable elements moving down into classes, types, and subtypes. 
(Unpublished) 
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The pol region of Copia/Ty1 elements has the order (PR, IN, RT) whereas the Gypsy/Ty3 
group has the more familiar arrangement (PR, RT, IN), which is also the order found in a 
majority of endogenous and exogenous retroviruses. 
The non-LTR retrotransposon class in humans has two sub-classes long 
interspersed nuclear elements (LINEs or Ls) and short interspersed nuclear elements 
(SINEs). There only two SINEs (SVA and Alu) and one LINE (L1) thought to be active in 
primates from these sub-classes. L1 has an autonomous retro-transposition through an 
RNA intermediate by two open reading frame proteins ORF1p, a nuclear acid chaperon, 
and ORF2p, an endonuclease and reverse transcriptase [134]. L1s constitute a large 
portion of the human genome, however only 80 to 100 are thought to be actively 
replicating and transposing.  L1 integration is initiated by ORF2p nicking the target DNA, 
which serves as a primer for the local reverse transcription of ORF2p. SINEs are short 
non-autonomous retrotransposons that are amplified in the genome via LINE machinery 
[135]. However, they do not require the ORF1p for transposition [136]. SINE -VNTR-Alus 
(SVAs) are on average ~2kbp long with a hexamer repeat region, an Alu-like region 
consisting of two antisense Alu fragments, a region of variable tandem repeats, a HERV-
K10 env and LTR region and a poly-A signal ending with an oligo(dA) – rich tail. There 
are suggestions of RNA polymerase II being the transcribing factor, however there is no 
internal promoter and possibly relies on promoter activity in flanking regions [137, 138]. 
The Alu repeat is > 500 bps long and has a dimeric structure formed by the fusion of two 
monomers from the 7SL RNA gene [139]. The 5’ region contains an internal RNA 
polymerase III promoter (A and B boxes) and ends with an oligo(dA) – rich tail of 
different lengths [140]. Alu’s do not possess RNA poly III termination signals and instead 
extend until a terminator (usually repeat thymines) is found [141]. 
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Class II transposable elements are DNA transposons (Figure 1.3). These elements 
are a “cut and paste” mechanism, which means they do not use an RNA intermediate like 
class I transposons. Most DNA transposons encode a transposase protein flanked by 
terminal inverted repeats (TIRs). The autonomous group of DNA transposons are further 
subclassified into several groups, which include Tc1/Mariner [142], piggyBac [143-145], 
and hATs [146, 147]. The nonautonomous DNA transposons are miniature inverted-
repeat transposable elements (MITEs) [147], which do not have transposases and act as 
microRNAs [148].  
 
1.2.2 Transposition Properties & Consequences of Transposition 
  It has been reported that about half of the human genome is made up of repeat 
elements and that the TE’s activity in the genome has been in decline [149]. The 
accumulation and movement of TEs can be attributed to their selfish replicative nature 
[150, 151]. Many studies have attributed TEs with influencing chromosomal structure and 
rearrangement. Furthermore, TEs have been implicated in mutagenic activities. 
1.2.2a Insertion Mutagenesis and Chromosomal Rearrangement 
More than one hundred human inherited diseases have been causally linked to de 
novo germline TE insertion mutagenesis disrupting a wildtype gene function [152, 153]. 
For example, a de novo transposition and insertion of Alu Ya5 SINE retrotransposon in 
the ALMS1 coding sequence was found in a Turkish cohort to drive Alström Syndrome 
[154]. LINEs make up the majority of these active transposition events [155]. In somatic 
cells, LINE insertional mutagenesis has been implicated in tumorigenesis and malignancy 
[156-158]. Additionally, TEs have been linked to several types of cancer by inducing 
chromosomal rearrangements in somatic cells [159]. There is little evidence for LTR 
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retrotransposons actively transposing to cause mutations in humans [74, 77, 149], 
however the potential to cause mutations has not been ruled out. Conversely, in mice LTR 
retrotranspositional activity inducing mutations is well documented [160, 161]. 
1.2.2b Insertional Site Preference and Selection  
Deep sequencing technologies and classical genetic approaches have provided 
detailed resolution about the integration site selection of TEs. TEs may integrate in 
sequence specific locations, chromatin domains, chromosomal regions, or all along 
chromosomes. Furthermore, TEs may integrate in a given preferential position but can 
be subsequently selected to integrate in different specific locations.   
Integration and selection preferences can vary among of mammals, including 
primates and humans. In humans, L1 TEs are by far the most active but the apurinic-
apyrimidinic endonuclease of L1 does not appear to have a site specific preference in the 
genome integrating in a dispersed manner with a bias for AT rich regions [162]. The SINE 
Alu, which utilizes L1 machinery in trans for replication behave in similar manner for AT 
rich site selection de novo. A majority of L1 transposition sites were rendered inactive due 
to a 5’ truncation that commonly occurs during its insertion [163]. DNA transposons 
encode a transposase that bind inverted repeats flanking the coding sequence of the 
transposon. The transposase is responsible for excising and transposing the DNA TE to 
double stranded DNA that has an identifiable short nucleotide sequence [164, 165]. LTR 
retrotransposons also recognize short nucleotide sequences that usually ensure DNA 
flexibility for the molecular manipulation required for integration [166-169]. Recent 
studies to elucidate integration patterns of endogenous and exogenous retroviruses found 
insertions were more likely to occur in gene-rich regions near active histone marks [170, 
171].  
19 
 
1.2.2c Recombination at TE loci  
Due to the copy and paste mechanisms of many retrotransposons, they create 
multiple homologous regions in the genome that can induce deletions, duplications, or 
inversions of chromosomal DNA upon recombination events [172-174]. If the copy of the 
retrotransposon generated is identical and in the same orientation to the first copy, 
recombination may delete the sequence in between the two TEs. If the two copies are 
opposite orientation, then an inversion of the sequence between them may occur due a 
recombination event.  
 
 
 
 
 
 
 
1.2.3 Alternative Functions of LTR Retrotransposons 
Some of the observable consequences of actively transposing elements are often 
interpreted by scientists that LTRs act in a selfish manner to propagate its own DNA with 
potential consequence to be mutagenic. Currently, there is a lack of evidence for 
retrotransposition activity in humans because generally, LTRs are heavily silenced in the 
genome by DNA methylation (Figure 1.4A) and older LTRs are found greater than ~5kbps 
A. B. C. 
Key 
Methyl group 
Reverse  
Transcriptase 
Integrase 
New DNA locations 
Figure 1.4 Long Terminal Repeat Retrotransposons Mechanisms of Regulation and 
Transposition. Top 3A. DNA methylation represses LTR expression. Bottom 3A. Demethylated LTR 
is actively transcribed. 3B. Reverse transcriptase from LTR turns LTR RNA into a DNA. 3C. Integrase 
incorporates newly reverse transcribed LTR into novel genomic location. (Unpublished) 
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from native gene promoters, due to the negative impact on expression of proximal genes 
[175]. Despite their quiescent transposable activity, many LTRs exhibit tissue specific 
expression patterns [176-178]. For example, in mice dynamic changes in gene expression 
patterns are associated with the expression of specific TEs [179-181]. Furthermore, Göke 
et al. observed specific LTR families characterize the different stages of early 
embryogenesis in humans [182]. Recently, it has been established that many LTRs have 
been coopted for host use as promoters for coding and noncoding transcripts and ancient 
viral protein expression. These alternative functions are explored further below. 
1.2.3a LTRs as Alternative Promoters for Coding Transcripts 
 LTRs autonomously recruit cellular transcription factors (TFs) because they 
contain numerous transcription factor binding sites (TFBSs) within their LTR regions. 
These LTRs that contain TFBSs contribute to about 20% of functional binding sites in 
humans [183]. Many LTRs have tissue specific expression and measurable transcription 
levels. Interestingly, some LTRs act as promoters and drive tissue specific expression of 
genes, such as (but not limited to), ADH1C in liver, CYP19A1 and ~10% of ENTPD1 in 
placenta, and MKKs in testis (Figure 1.5A) [184-188]. Many LTRs generate gene variants 
due to their placement in introns and can act as an alternative promoter.  For example, in 
~11% of melanoma cases, a LTR insertion between exon 19 and 20 of ALK acts as 
alternative promoter, which generates an isoform that is constitutively active, promoting 
oncogenesis [189]. Many other examples of LTRs and other TEs acting as alternative 
promoters in cancer can be found here (Figure 1.5A) [190]. 
1.2.3b LTRs Derive Important Noncoding Transcripts 
Roughly 70% of lncRNAs are associated with a TE within their transcript and 
~30% of lncRNAs are derived (Figure 1.5B) directly from TEs. In a majority of genomes, 
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the distribution of TEs generating lncRNAs is proportional to the percent of genomic 
content they represent. Albeit in the human genome, LTRs, account for ~8% of the 
genome but make up the majority of the lncRNAs derived from TEs. Conversely, LINEs 
comprise ~40% of the human genome but have disproportionally low contribution in 
lncRNA expression [191]. Recently, it was found that HERV-H derived lncRNAs are 
highly and specifically expressed in hESCs [192, 193], define the naïve stem-cell state 
[194], and are essential for the maintenance of pluripotency [195]. There is evidence that 
lncRNA are not the only noncoding regions effected by TEs. For example, many 
microRNAs derived from TEs have also been described as having important regulatory 
roles for the host cell [196]. 
 
 
 
 
 
 
 
1.2.3c Exaptation of LTR ERV TEs as New Genes  
There are a few ERVs from the LTR retrotransposon family that have had their 
ancient viral genes “domesticated” for host use in placental functions, immune system 
roles, and neuronal activity (Figue 1.6). An interesting example comes from the 
TE Gene 
TFBP 
TE 
I) 
• Cancers: Breast and 
others 
A. 
B. 
Figure 1.5 Long Terminal Repeat Retrotransposons Alternative Functions. A. Alternative 
promoter for downstream gene with a TFBP that has a higher affinity for the TE promoter than its 
primary promoter producing high quantities of gene product. B. TE derived long noncoding RNA. 
TFBP transcription factor binding protein. (Unpublished) 
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independently co-opted syncytin genes from ERV env regions. The products of these 
genes have roles in cell-cell fusion, formation of the syncytiotrophoblast, and immune 
suppression of mammal hosts during pregnancy [197-201]. Another example of a viral 
particle being repurposed for host functions is the neuronal Arc gene, which is a remnant 
of an ERV gag gene [202, 203]. The protein product of the Arc gene is a multifunctional 
hub protein responsible for long-term synaptic plasticity which is critical for memory and 
cognition [204].   
 
 
 
 
 
1.2.4 Endogenous Regulation of TEs  
To ensure tissue specific expression of specific TEs and minimization of negative 
impacts on genome fitness TEs require tight regulation. In somatic cells, dense DNA 
methylation is thought to be the main repressor of TE expression and activity [205-209]. 
Thus, DNA hypomethylation or demethylation occurs in these cells, TEs are de-repressed 
[210-213].  
Interestingly, early germline cells and the early embryo are able to control TE 
expression activity without DNA methylation. These cells undergo global DNA 
demethylation and yet still rely on tightly regulated repression and transcription of TEs, 
LTR LTR Gag Env Pol 
E G 
• Expressed in many cancers 
Figure 1.6. Long Terminal Repeat Retrotransposon Viral Protein Exaptation. Expression of 
endogenous retroviral genes produce viral protein products, such as, viral envelope proteins (grey 
circle labelled E) and viral structural proteins (green circle labelled G). (Unpublished) 
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In fact the timing of the expression for specific TEs dictates the pluripotency of the cell 
[179, 214]. One mechanism of specific TE repression is with Kruppel-associated box zinc 
finger (KRAB-ZF) proteins whose numbers strongly correlate with the number of LTR 
elements in mammals [215]. The KRAB domain is responsible for recruiting TRIM28 
(also known as KAP1, Tif1β, and KRIP-1), which acts a scaffold for many proteins, such as 
SETDB1 a histone methyltransferase responsible for H3K9me3 marks [216, 217]. The 
major function of ~two-thirds of KRAB-ZFPs, inferred from genome-wide binding 
profiles or direct loss-of-function studies, is the binding, epigenetic marking, and 
repression TEs [218-221]. This suggests that KRAB-ZFPs play a major role in initiating 
stable epigenetic marks via de novo methylation of ERVs throughout embryogenesis 
[222]. Furthermore, ablation of the KRAB-interacting protein TRIM28 or SETDB1 
activates several TEs [223, 224]. Interestingly, there is experimental evidence that some 
KRAB-ZFPs function beyond early development and even control ERV expression in 
adult tissues [225]. These findings suggest a tight rope regulation of sequence specific TEs 
which may be necessary for tissue specific expression and activity.  
Further regulation in male gametes is obtained through piwi proteins and their 
associated piRNAs. Briefly, abundantly expressed TEs are spliced into pools of small 
RNAs that bind to PIWI proteins and guide them to target DNA sequences. The targeted 
sequences are silenced and maintained quiescent until de novo DNA methylation occurs 
[226-228].   
Finally, in differentiated cells, evidence of chromatin modifications associated with 
condensed repressed states at TE insertions provides further regulation beyond DNA 
methylation.  Chromatin modifications that prevent transcription initiation at these TE 
insertions are methyl marks at histone 3 lysine 9 and 27 (H3K9me and H3K27me). 
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Additionally, there is a lack of transcription initiation chromatin marks at TE locations, 
such as histone acetylation [229-231].   
 
1.3 Introduction to Transcriptomics 
Transcriptome analysis allows for the detection differentially expressed genes in 
breast cancer vs. non-diseased tissue that may drive its pathogenesis. The variety of 
technologies available to researchers makes choosing the most appropriate platform to 
address and resolve specific scientific problems (or hypotheses) using transcriptome 
analysis a daunting task. While some researchers believe microarrays are the most 
reliable due to their maturity, others embrace next-generation sequencing (NGS) as the 
superior method because it is the current vanguard of molecular technology. Assumptions 
in data analysis can skew and obscure data interpretation of gene expression if the 
hypothesis and, most importantly, the experimental design don’t mitigate the 
shortcomings of each platform. After gene expression has been measured, the researcher 
must also choose from numerous software programs and analyze expression data. 
Therefore, the goal of this section is to provide brief explanations of the history, strengths, 
and limitations of transcriptomics technologies as it pertains to gene expression analysis 
as a resource guide to interpreting transcriptome experiments within the context of 
clinical data. 
 
1.3.1 Materials and Methods Used for Transcriptomic Studies 
Transcriptome analysis creates a detailed molecular synopsis of cellular physiology 
by elucidating the mRNA available for translation and/or the abundance of the various 
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transcripts, such as noncoding RNAs or microRNAs. Techniques used in transcriptome 
analysis belong to two broad classes; hybridization-based or sequencing-based. These two 
types of transcriptome analyses are versatile to examine differential gene expression in 
many cellular physiological contexts, comparing developmental stages, cell cycle, or in 
disease states. The time and cost of transcriptome analysis has been greatly reduced by 
the development of microarrays and, more recently, NGS, particularly when compared to 
older large-scale gene expression analysis technologies such as serial analysis of gene 
expression (SAGE), expressed sequence tag (EST) libraries, differential display, etc. Given 
the variety of factors affecting breast cancer and the multiple pathways involved, 
transcriptomics is a useful tool for diagnostics, discovery science, and pinpointing 
molecular mechanisms in both clinical and translational models. Transcriptomics also 
provides a way to identify and test novel treatments and therapeutics that directly correct 
the underlying breast cancer, in addition to novel therapeutic approaches to alleviate 
symptomology. 
 
1.3.2 Gene Expression Analysis History of RNA Identification 
1.3.2a Sanger sequencing  
Sanger sequencing is the invention fundamental for developing modern methods, 
such as NGS, to sequence for expressed genes in transcriptomic studies. Sanger 
sequencing is the first-generation method of determining DNA nucleotide sequence based 
on chain-termination idea developed in 1975. Modern modification of this classic method 
is based on in vitro DNA elongation of query template, which is interrupted by occasional 
incorporation into nascent DNA strands of differently labeled di-deoxynucleotide 
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triphosphates (ddNTPs) present in the reaction mixture along with dNTPs. Unlike dNTP, 
incorporation of a ddNTP halts extension of synthesized strand; because ddNTP is 
labeled, the synthesized fragment is detected as a single band of certain color after size 
separation, and collection of these bands represents DNA sequence [232]. Expressed 
genes are identified using various methods to harvest RNA to make and use cDNA for 
expression studies, including subtractive cloning, EST, SAGE, differential display 
analysis, and microarray analysis. Once identified, gene interactions with other genes can 
be pursued experimentally [232]. 
1.3.2b Subtractive Cloning 
Subtractive cloning is an inexpensive and readily available technique in individual 
biomedical and clinical laboratories to analyze gene expression using basic molecular 
biology resources and bioinformatics tools. A sequence, the “tracer” is hybridized with a 
complementary sequence, the “driver”, which is missing a sequence of interest. The two 
sequences are combined, and reannealing is dictated by the driver, which is present at 
least 10 times higher than the tracer. Once annealed, driver-tracer complexes are removed 
in the subtraction step which is repeated until all common sequences are annealed and 
removed. The remaining tracer sequences create a tracer specific library that represents 
differentially expressed genes. Hybridization of cDNA may cause some bias for small 
fragments of cDNA that hybridize faster than long sequences, but is resolved by PCR 
amplification [233]. 
1.3.2c cDNA Libraries and Expressed Sequence Tags (EST) 
In the late 1970s, cDNA libraries [234] became popular for gene discovery and 
expression analysis, as the library clones were stable, reproducible, and recoverable 
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representations of mRNAs isolated from distinct organs and species [235, 236]. The idea 
to execute Sanger sequencing of many (i.e., >1,000) library clones to understand gene 
expression in a given tissue spurred the EST project [237]. ESTs are derived from cDNA 
libraries by random sampling, followed by arraying the sampled clones for future use, and 
then executing a single sequencing reaction for each clone. Most expressed genes can be 
unambiguously identified through these relatively short (~ 300-500 nt) EST sequences. 
Data are collected using automated DNA sequencers and analyzed using bioinformatics 
tools. ESTs are clustered and assembled to construct consensus sequences using, e.g., 
CAP3 program [238]. Meaningful data are generated with high throughput preparation 
of either normalized or non-normalized cDNA libraries [239]. ESTs allow for de novo 
gene discovery [235, 236], and large-scale prediction of gene products and function [240, 
241]. An EST warehouse with high-quality data, including breast epithelium and breast 
cancer, can be found in Unigene and ENSEMBL. Unigene uses reference sequences along 
with Genbank mRNAs for cluster generation, and contaminants, low-complexity and 
repeat sequences are identified with RepeatMasker and DUST [239]. 
1.3.2d Serial Analysis of Gene Expression (SAGE)  
The next development in transcriptomics was Serial Analysis of Gene Expression 
(SAGE) in 1995. SAGE constructs cDNA libraries in a similar fashion to ESTs but using 
shorter tags to identify genes. Libraries are constructed by using restriction enzymes and 
primer “linkers” ligated into the fragments encoding a recognition site for type II 
restriction enzyme [242]. The cDNA fragments are then amplified and digested resulting 
in the production of a 13-20 base pair cDNA fragment or “SAGE tag” and are associated 
with the initial four base pair restriction enzymes. One advantage of the SAGE method is 
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high-throughput sequencing resulting from its pairing with an automated sequencer 
although the bioinformatics tools required to analyze the libraries are highly specialized. 
SAGE analysis can be successfully used for de novo expression profiling, but the short 
length of the SAGE tag can impair differentiating between highly homologous genes. 
1.3.2e Differential Display Analysis  
Differential Display is a PCR-based method to measure differential gene 
expression. Differential Display reverse amplifies mRNA transcripts using primers from 
random sequences and visualized using gel electrophoresis. The presence of a band 
confirms gene expression and its intensity represents relative amount of transcript [243]. 
Differential display detects all expressed genes without using specific primers, making it 
a robust, inexpensive discovery tool. Current advances in Differential Display incorporate 
the use of fluorescent labels with automation to yield high throughput analyses [244, 
245]. 
1.3.2f Microarray Analysis  
In 1995, cDNA microarrays superseded the method of Differential Hybridization, 
introducing the use of miniature spotted DNA probes and fluorescent labeling of sample, 
reducing the redundancies after hybridization. Pools of known cDNAs (spot) in indexed 
locations on glass slides represent known genes. Total sample mRNA is reverse 
transcribed, cRNA amplified by in vitro transcription, and then hybridized to microarray 
slide. The intensities of the spots produced are then recorded and analyzed by computer 
software to determine the expression level of a gene [232]. One advantage of cDNA 
microarrays over EST or SAGE is the ability to analyze gene expression differences under 
various experimental conditions concurrently by using different fluorophores during the 
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cRNA transcription. Examples of microarray technology use in breast cancer research are 
X, Y, and Z. Microarray analysis requires substantially less poly(A) RNA (0.5-2.0 µg) 
compared to cDNA libraries or Differential Display methods, albeit typical limitations are 
the quality, specificity and signal discrepancy of the probes on the array. After 
introduction, microarray analysis became commonplace and made labor-intensive cDNA 
and SAGE libraries essentially obsolete, despite this method’s restriction to previously 
discovered transcripts only (e.g. identified via EST libraries) and its inherent inability to 
discover novel genes, alleles, or splice variants [246]. With its high throughput method 
requiring low manual labor, low amount of starting RNA, and streamlined bioinformatics 
processing, microarrays provide an attractive alternative to sequencing for large-scale 
transcriptome analysis. 
 
1.3.3 Next-Generation Sequencing and Deep Transcriptome Analysis 
Second generation sequencing techniques emerged in 2005 and equipment 
fundamentally differs from first generation sequencers because multiple different DNA 
molecules are sequenced concurrently. As a result, tens of thousands to hundreds of 
millions of individual sequencing reads are produced with each run. Different principles 
underlying sequencing and detection and different chemistries behind various platforms 
lead to large differences in read length, base call accuracy, and total number of output 
reads. The largest obstacle for second generation sequencers is obtaining read length to 
read quality ratios comparable to Sanger sequencing, with most platforms producing 
average reads with less than 300 bases. In addition, the samples are sequenced in a stop-
read-start manner that leads to lengthy processing times, with some platforms requiring 
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over a week for a single run to complete. To make these platforms economical, the number 
of reads per run has been increased through the introduction of larger machines, such as 
the Illumina HiSeq series, or denser chips, in the case of Ion Torrent. However, the larger 
sequencers have a substantially higher price and require processing at full capacity to 
benefit from the increased throughput and, consequently, are not typically found in 
individual laboratories or small research consortia. There are smaller platforms available 
from Illumina, 454 Roche, and Ion Torrent that produce longer length reads than the 
larger sequencers, thereby suit the needs of small laboratories [247]. 
1.3.3a Basic principles of NGS sequencing 
All second-generation sequencing platforms require modification and 
amplification of sample DNA. Samples are fragmented, and adapters are annealed to the 
ends. For platforms that use emulsion PCR (emPCR) to amplify the samples, the adapters 
allow the fragments to bind to complementary bases on the emulsion beads. SOLiD 
sequencing further modifies the fragments after amplification by adding regions that 
allow the fragments to covalently bond with the sequencer slide. The Illumina platform 
uses a bridge PCR to amplify the samples, which have been modified with adapters to the 
base pair with oligonucleotides embedded on the sequencer slide. 
Each platform also employs a different method for generating the base calls for 
each sample, but only Ion Torrent does not use a light-based recording method. The base 
calls are reported by pyrosequencing in 454 Roche platforms, and by fluorescent tag 
cleavage in Illumina and SOLiD platforms. The Illumina platform produces forward and 
reverse reads from each DNA fragment and SOLiD identifies each fragment’s bases twice, 
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thereby increasing accuracy. Ion Torrent uses a microchip with pH meters incorporated 
into each well to detect the release of an H+ ion with each base incorporated.  
Extension of fragments occurs during sequential “flooding” of the sequencing 
reaction chamber with solutions containing specific nucleotides. Illumina differs from 
other platforms by using a reaction mixture containing all 4 nucleotides. The Illumina 
nucleotides are modified with a fluorescent group plus a terminator to prevent 
introduction of additional bases in the cycle. The fluorescence is recorded, and its tag 
cleaved before flooding the sequencer with the nucleotide-containing reaction mixture 
again. In pyrosequencing, the nucleotides have a modified pyrophosphate group that is 
cleaved after addition. SOLiD sequencing uses di-base oligonucleotides with a 3-base 
extended region and a fluorescent tag. An (n+1)-long primer is added after each round of 
synthesis which, after 5 repetitions, emits two base signals for each incorporated 
nucleotide. Nucleotides in Ion Torrent sequencers are added in alternating floods of A, T, 
C, and G. As each base is paired to the fragment, an H+ ion is released and detected by the 
sequencer microchip. 
1.3.3b Development of single-cell RNA sequencing strategies  
The recent ability to interrogate the transcriptome of individual cells using second 
generation sequencers has revealed heterogeneity in gene expression of individual cells 
within a population. As the name implies, single-cell RNA sequencing (scRNA-seq) relies 
on the isolation and amplification of transcriptomes from individual cells, and many 
different isolation and amplification strategies have been developed, such as Cel-seq2 
[248], Smart-seq2 [249] and Drop-seq [250]. Isolation of individual cells is accomplished 
by using microfluidic capture chips (Cel-seq2), fluorescence activated cell sorting (Smart-
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seq2), or droplet emulsion (Drop-seq). Most scRNA-seq protocols, excluding Smart-seq, 
incorporate cell-specific barcodes during the reverse transcription reaction that allows for 
a large amount of multiplexing. Smart-seq, in contrast to other scRNA-seq methods, 
generates full length cDNA and can more accurately differentiate between splice variants. 
A  side-by-side comparison of these scRNA-seq strategies found that Drop-seq was the 
most cost-effective method, whereas Smart-seq was the most accurate [251]. Analyzed 
cells may be clustered based on expression levels of selected genes either to detect changes 
in cell populations or within a population induced by a disease. 
1.3.3c Strengths & Caveats for Transcriptome Analysis  
Next generation sequencers are powerful tools, but they are not without flaws and 
errors that can arise at any step of the sequencing process. Firstly, errors may be 
introduced by polymerase during the amplification of sample cDNA, and research 
indicates this may be the primary source of errors in second generation sequencing data 
[252]. Secondly, errors originate from the chemistry used by the various platforms, and 
often manifest in nucleotide substitutions, insertions, or deletions [247]. The error rates 
of second-generation sequencers are principally increased in homopolymeric regions 
caused by incorporation of multiple bases in a single cycle. AT-enriched regions and 
genomes cause increased error rates in next generation sequencers possibly from PCR 
artifacts and nonrandom fragmentation of sample DNA [253]. Errors due to AT-richness 
are most pronounced in the Ion Torrent platforms [254]. Furthermore, when utilizing 
single-cell sequencing strategies, comparison between samples can be greatly impaired 
by poor matching of samples, the stages of disease progression, and the variability 
between individuals can compound the inherent heterogeneity that is present when 
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comparing individual cells. While the ability to determine the response and contribution 
of individual cell types to disease progression is important, more samples are necessary 
to identify and distinguish between inter-individual and intra-individual variation. 
For next-generation RNAseq analysis, the most important parameters to consider 
in experimental design to substantially increase the quality of downstream analysis are: 
the number of biological replicates, the depth of sequencing (i.e., number of reads 
produced for each sample), read length, single-end vs. pair-end sequencing (i.e., each 
sequenced DNA molecule is represented by a single strand read vs. two reads from each 
strand), and RNA extraction. Under budgetary constraints, tradeoffs between sequencing 
depth and the number of biological replicates are often made. As consistently reported, 
the requisite number of biological replicates (n=3-4) is more critical for robust, reliable, 
and replicable analysis than sequencing depth [255-258]. As technologies improve, 
sequence lengths increase. For differential expression, little difference is seen if the length 
is >25 bps, in either single-end or pair-end sequencing. However, for greater accuracy in 
transcript identification and splice junction detection, reads should be pair-end and ≥100 
bp [259]. The RNA extraction method impacts the ratio of RNAs present during 
sequencing, and a specific strategy should be chosen with the biological or biomedical 
question of interest in mind. For example, total RNA extraction is useful in capturing 
unique transcriptome features, such as noncoding RNA. However, ribosomal RNA 
(rRNA) comprises >90% of total RNA and should be depleted if noncoding, non-
ribosomal RNA is to be assessed. Current techniques cannot completely remove rRNA, 
and ~2%-35% residual remains in the sample. Therefore, greater sequencing depth 
should be considered when using ribosomal depletion methods to counter the abundance 
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of rRNA and improve detection of other transcripts. In eukaryotic organisms, if only 
protein coding genes are of interest, poly(A) selection yields greater accuracy of transcript 
quantification [260]. These issues are particularly critical for clinical samples from 
patients, which are routinely processed as formalin-fixed, paraffin-embedded (FFPE) 
samples, which adversely impact the quality of RNA. Fortuitously, side-by-side 
comparison of FFPE and flash-frozen samples shows a great degree of concordance (e.g. 
r2 in the range of 0.90-0.97 in recent studies [261, 262]), proving RNAseq is a viable tool 
for gene quantification in clinical settings. Controls, depending upon availability, need to 
be non-diseased tissue, either of the same patient origin or from another individual 
without the disease [263]. In addition, given breast cancer is a common disease, patients 
are from genetically diverse, heterogeneous populations with variable symptomology, 
which requires more samples to detect meaningful changes in the transcriptome truly 
reflecting disease process. However, in other studies, such as breast cancer, as few as n=9-
10 patient samples (plus samples of healthy controls), have been ample to detect specific 
alleles and molecular pathways [263]. 
Despite the errors that may occur when using second generation sequencers, 
several advantages over previous transcriptome technologies warrant their use 
experimentally and clinically. First of all, second generation sequencers offer orders of 
magnitude deeper coverage of sample RNA than achieved by Sanger sequencing, via EST 
libraries, yielding overall faster discovery and more accurate analysis of an entire 
transcriptome. Also, the length and quality of sequence produced by second generation 
sequencers are much better than the fragments produced in SAGE, which improves 
transcriptome accuracy. While EST typically produces fragments of at least 500bp, most 
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second-generation sequencing produce shorter read lengths, albeit, read length from 
second generation sequencers can be increased at the expense of read depth. Next 
generation sequencers have advantages over microarrays because essentially all 
expressed transcripts and their variants, can be detected, without restriction to the probes 
present on the microarray chip or beads [264], plus the ability to barcode different 
samples, or conditions, within a single sequencing procedure permits multiplexing of 
samples. 
 
1.3.4 Third Generation Sequencing 
The latest generation of sequencers is distinguished from first and second 
generations by eliminating sample amplification. Bypassing sample amplification reduces 
sample preparation time and eliminates signal mismatch and distortion errors introduced 
during amplification. In addition, these single-molecule sequencers produce extremely 
long reads, surpassing the lengths achieved by Sanger sequencing. The Pacific Biosciences 
Single Molecule Real Time (SMRT) sequencer utilizes pyrosequencing (Fig 5) in 
polymerase-embedded plates, which lower the signal-to-noise ratio to detect real-time 
signal processing of fluorophore cleavage. The use of pyrophosphate-labeled nucleotides 
in polymerase-containing plates to extend DNA at near its natural speed facilitates 
processivity and sequencing length. Another third-generation sequencing platform 
available now is nanopore sequencing (MinION, Oxford Nanopore Technologies). This 
technology utilizes electrophoresis of DNA molecules via nanopores (5-8 nm diameter); 
as the DNA molecules squeeze through the pore, each nucleotide (A, T, G and C) produces 
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a unique electromagnetic signature detected. Similar to SMRT, nanopore sequencing can 
produce very long reads, up to 880 kb in a recent report [265]. 
1.3.4a Strengths & Caveats for Transcriptome Analysis  
The Nanopore and SMRT sequencer both have ~10-15% error rate, distributed 
evenly over the length of the read [265]. Fortunately, the lack of location bias in SMRT 
and Nanopore reads provide sufficient coverage to extrapolate highly accurate consensus 
sequences. Third generation sequencers are not yet ubiquitous, but they promise several 
advantages over previous generation sequencers. The lack of sample amplification allows 
for quicker, cheaper analysis and avoids the polymerase errors caused by amplification. 
The long reads generated by third generation sequencers allow for more accurate 
assembly of large contiguous sequences, such as whole chromosomes, complete 
sequencing of whole genes in a single read [266], and identification of novel transcript 
isoforms. These platforms are excellent for whole-genome and whole-transcriptome 
assemblies [267, 268], including complex genomes such as gorilla [269] and human 
[265]. However, at this time, third generation sequencers are at a disadvantage for use in 
transcriptome analysis for quantification of expression due to the relatively low number 
(e.g. ~50,000 for RSII sequencer) of output reads generated with each run comparing to, 
e.g., Illumina sequencers (current typical low-end is 20,000,000+ reads per sample). The 
long reads greatly improve de novo assembly and transcriptome analysis for gene isoform 
identification, and the emerging technology in the field of metagenomics, which may be 
important for investigating the role of microbiome imbalance in breast cancer patients. 
Longer reads are also useful when assembling genomes that include large stretches of 
repetitive regions. These technologies are recommended for whole genome assembly and 
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splice variant detection albeit given the error rate currently not recommended for 
transcript quantification. 
 
1.3.5 Results of Transcriptome Analysis: Unbiased Data Mining  
1.3.5a Differential expression analysis  
In most cases, comparison of one or more conditions will result in a ranked list of 
transcripts with either relative or absolute levels of expression. The typical approaches 
include (1) raw data collection (processing of image files to collect intensities for 
individual probes on microarrays, counts of number of reads per transcript for RNAseq 
data, etc.); (2) data normalization, often followed by transformation [270]; (3) statistical 
analysis to identify transcripts whose expression differences between conditions are 
significant, and most importantly, (4) downstream analysis. 
Microarrays of any platform are substantially more rapid to process using the 
manufacturers’ software suites, such as Affymetrix’s Expression Console and 
Transcriptome Analysis Console, or Illumina’s GenomeStudio. Alternative open-source, 
peer-reviewed, and publicly available software for microarray analyses using the R 
programming language, such as affy [271], lumi [272] and limma [273], are available as 
installation packages from the Bioconductor portal [233]. 
For next-generation RNAseq analysis, the most important parameters to consider 
in experimental design that substantially increases the quality of downstream analysis are 
depth of sequencing (i.e., number of reads produced for each sample, also referred to as 
“coverage”), read length, and single-end vs. paired-end sequencing. These parameters 
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vary based on the goal of the biological or clinical experiment. For example, comparison 
of expression between samples requires far less read depth than identification of novel 
transcripts or splice variants. Journals that publish RNAseq studies sometimes also have 
their own requirements for read depth. Furthermore, the length of sequencing reads 
varies depending on experimental design, with longer reads typically being used in novel 
transcript identification or de novo assembly generation [268]. Sequence read lengths as 
low as 75 bases are sufficient for differential expression analysis [256]. Finally, paired-
end sequencing from both ends of a single mRNA fragment facilitates identifying splice 
variants and alignment [259]. 
Once the sequence is obtained from the raw signals, the quality of the output must 
be assessed, based on sequence read lengths and processing direction (single-end vs. 
paired-end sequencing) with either FastQC [274] or NGSQC [275]. These tools will 
provide GC content, overrepresented reads, PCR artifacts, and sequence quality to detect 
potential PCR bias or DNA contamination. It is usual for sequence quality to weaken at 3' 
end and software programs, such as Trimmomatic [276] or FastQ trimmer [277], can 
remove these low-quality 3' ends. Alignment is a critical step in RNA sequencing analysis 
because raw sequence reads must be mapped precisely to an annotated reference genome 
or transcriptome for the species. While it is possible to analyze RNAseq data without a 
reference, e.g. by using Trinity software [278], most clinical and translational models of 
breast cancer have assembled genomes available. The most common software platforms 
to align RNA sequence to a reference genome are TopHat [279], HiSAT [280], and STAR 
[281]. These platforms differ with respect to speed, memory usage, and their algorithms 
for handling base and splice junction alignment precision, with HiSAT and STAR 
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optimized to process large datasets (>108 reads), whereas TopHat is designed for smaller 
datasets (<2×107 reads). 
Measurement of transcript expression in RNAseq data is based on quantifying raw 
counts at each genetic locus along the chromosomes using an assembled genome with 
programs such as HTSeq-count [282] or featureCounts [283]. This approach uses a GFF 
(Generic Feature Format) or GTF (General Transfer Format) file that contains gene 
coordinates, identifiers, and descriptions in a strict predefined format [284]. All the reads 
that map within the genomic coordinates of a given feature (e.g., gene, exon) contribute 
to the count number of this feature. The counts from the RNAseq data are corrected for 
sequencing depth and often for length of gene transcripts because smaller datasets will 
have fewer count numbers, with the consequence that longer transcripts will have higher 
representation among raw RNAseq reads. The majority of normalization methods report 
the amount of transcript expression as reads per kilobase of exon per million reads 
(RPKM), fragments per kilobase of exon per million of reads (FPKM), transcripts per 
million (TPM), or counts per million (CPM) [285-287]. 
   1.3.5b Enrichment Analysis: Overview of Biological Ontologies  
Description of gene functions in scientific literature can vary significantly between 
authors, even if both are describing the same phenomenon. Consequently, unbiased 
grouping of genes by functional similarities may become a daunting endeavor. To 
facilitate the task of describing the universe of genes, the methods of formal ontology were 
applied to create the first controlled vocabulary to standardize gene descriptions across 
species and disciplines. The resulting Gene Ontology (GO), and GO Consortium were 
formed in 1998 to create a framework for standardizing gene products description [288]. 
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Since inception, GO was used to annotate millions of genes, with over 1,350,000 
annotations for H. sapiens, R. norvegicus, and M. musculus genes alone. The highest-
level annotations for genes in GO are a trinity of molecular function, cellular component, 
and biological process. Currently, GO uses 29,623 “Biological Process”, 11,139 “Molecular 
Function”, and 4,189 “Cellular Component” terms, and strict rules to describe evidence 
linking a gene to a term (from relatively vague “Inferred from Sequence or structural 
Similarity” to strong “Inferred from Experiment”), to annotate genes across the tree of 
life; taking into account the total number of annotated genes in species, currently average 
number of annotations ranges from 5 for E. coli to 21 for R. norvegicus. GO is organized 
as a graph, with individual terms being nodes, and relationships between terms being 
edges. Currently, there are 8 types of relationships between terms, and the “is_a” 
relationship gives this ontology a loose hierarchy, with more general terms being “parent” 
to more specific “child” terms [288]. Curation remains an ongoing process, including the 
field of breast cancer, and new annotations, and new GO terms are added frequently as 
scientific and specific knowledge expands. The dynamic nature of GO catalyzes new 
discoveries to be readily integrated into the existing ontology while older annotations are 
updated with new information as it becomes available. Following the success of GO, other 
ontologies began to emerge to formalize biological and biomedical knowledge to assist in 
large-scale data analysis and discovery of new treatment avenues. Relevant examples 
include Mammalian Phenotype Ontology [289] and Human Phenotype Ontology [290], 
both used to formalize descriptions of normal and breast cancer phenotypes. Another 
example, Protein Ontology, describes evolutionary relation, isoforms, and complexes of 
proteins [291, 292]. These and other ontologies collectively form an Open Biological and 
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Biomedical Ontology (OBO) Foundry and share common goals to facilitate curation, 
management, distribution, and analysis of data [293]. 
Analyzing the data produced from transcriptome analysis facilitates researchers to 
explore gene functions, expression levels, differential gene expression, organismal 
responses to environmental and developmental changes, and more. Understanding these 
characteristics can allow for the identification of highly specific drugs or disease 
biomarkers. When analyzing transcriptomes of samples, the key focus is the difference of 
expression levels of various groups of genes. 
1.3.5c Using Ontologies & Pathway Analysis for Precision 
Medicine in Breast Cancer  
Precision medicine classifies individuals according to their underlying 
susceptibility, prognosis, or targeting potential treatment response. Unlike DNA 
sequencing focusing on genome, RNA sequencing produces the snapshot of the full 
transcriptome, and has the capability to fulfill precision medicine to classify patients at 
both molecular and cellular levels when used in conjunction with programs for ontologies 
and pathway analysis. Development of RNA sequencing pipelines is important for 
implementation of transcriptomics as precision medicine [294], which can be used 
successfully to classify patient or model attributes and predict therapeutic response and 
ultimate outcomes. Classifying patients based on symptoms is limited because symptoms 
often arise from numerous origins or multimodal pathways, as the case with breast 
cancer. Biomedical researchers in both clinical and basic research settings need to choose 
transcriptome analysis to the specific characteristics of disease, and its pathology, to 
detect changes in the target molecular, cellular and physiological pathways under 
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scientific scrutiny. Transcriptomics is a robust method to measure both common and 
unique pathways simultaneously. For unbiased detection in molecular and cellular 
pathways, researchers need to use a variety of tools, from read alignment to ontological 
analysis. 
The first step of ontological analysis of genes is its annotation for its biological 
process, cellular component, and molecular function. Once all the gene annotations have 
been collected, they are grouped by category, and these categories are analyzed for 
enrichment or depletion against a “universe set” of all the genes of an organism. The 
number of annotations to a distinct ontological term in a list of genes, for example, a list 
of downregulated genes in invasive ductal breast cancer (IDC) vs. normal breast 
epithelium is compared to the number of annotations to this term among genes in the 
universe set (i.e., all genes in the genome) to identify if the occurrence of this term in the 
experimental results is higher or lower than expected from a random sampling of the 
universe set. This analysis facilitates discovery of common biological themes, based on 
ontologies, within the lists of genes. Multiple tools exist for determining pathway 
enrichment; among preferred tools in our laboratory is the VisuaL Annotation Display 
(VLAD [295]), which allows to define the “universe set”, simultaneously use more than 
one query set, as well as operate with any ontology within OBO Foundry, rather than only 
GO. 
In particular, the ability to upload own “universe set” of genes allows for more 
precise identification of over- and underrepresented ontologies, while the ability to 
upload any ontology from OBO Foundry allows exploration of additional ontologies such 
as Mammalian Phenotype [289]. Importantly, in the online version of VLAD, GO 
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annotations, as well as nomenclature of mouse and human genes are updated weekly 
automatically [295] although local installment of VLAD requires the individual laboratory 
to manually update gene annotations from GO. Similar tools, such as AmiGO [296], 
BiNGO [297], DAVID [298], GOrilla [299], are also very popular free public resources to 
identify GO term overrepresentations in the lists of genes, however, many of these 
excellent tools lag behind in updating their gene annotations by as much as 3-4 years. 
Similar idea of measuring and testing overrepresentation within a group of genes of 
interest is implemented in Gene Set Enrichment Analysis (GSEA) [300], and commercial 
platforms such as Ingenuity Pathway Analysis (IPA) [301] and Pathway studio [302]. 
Another useful tool to identify specific pathways in the large-scale gene expression 
data is MetaCyc [303], which contains a collection of curated biochemical pathways, 
annotated with organism-specific data on genes, pathways, proteins and compounds. 
MetaCyc tool, Cellular Overview, allows the user to upload gene expression data and 
visualize the expression upon the entire metabolic map while simultaneously retaining 
the ability to focus on individual pathways affected by disease or condition, such as atypia, 
DCIS, or IDC samples from breast biopsies [85]. For mammals, curated databases include 
human [304], mouse [305] and cattle [306]. Differentially expressed gene lists can also 
be overlaid onto existing cellular pathways using portals such as Reactome [307] or the 
Kyoto Encyclopedia of Genes and Genomes (KEGG) [308] to explore potential secondary 
pathways, and dysregulated pathways specific to breast cancer pathology or healthy 
samples. Importantly, research community involvement in the process of gene annotation 
and curation, including creation of disease-specific ontology terms, improves the 
precision and quality of these resources to breast tissue and breast cancer research [309]. 
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1.3.6 Summary of Transcriptomics Approaches 
Transcriptome analysis is a dynamic tool, whose efficacy and efficiency are 
continually improving. The variety of platforms available to perform such analyses is a 
great advantage to laboratories both large and small, and the high-throughputs for some 
of these technologies provide rapid results with great accuracy. Identification of affected 
pathways using transcriptomics bioinformatics tools allows researchers and clinicians to 
make a focused and informed decision on the genes to concentrate on as potential 
therapeutic targets in precision medicine. Application of transcriptomics can facilitate the 
exploration of underlying pathogenic mechanisms, identification of genetic variants, 
determination of treatment effects, including screening for molecular biomarkers. 
Importantly, expression signatures in diseased phenotypes may pinpoint precise 
interventions required to alleviate the disease state, a goal of precision medicine, without 
a need for the cost prohibitive personalized assembly and deep analysis of patient’s 
genome. Thus, transcriptomics can classify individuals while simultaneously facilitate 
discovery, testing, and validation of new therapeutics for patients with breast cancer, 
defined at the cellular and molecular levels. 
 
1.4 Objectives, Hypotheses and Aims of Studies  
Great efforts have been made to determine the etiology of human invasive breast 
cancer. Currently, many studies have identified several risk factors and mutated genes 
associated with breast cancer.  However, the components contributing to malignancy 
progression from DCIS to IDC are unknown and there is unmet need for prognostic 
markers to identify patients that will develop malignancy. Interestingly, a recent study, 
using spatially resolved single-cell genome sequencing, posits that in DCIS to IDC breast 
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cancer, genome evolution occurs early in tumor progression and prior to invasion [310]. 
This study is counter to the bottleneck theory that suggests a single clone is selected for 
basal membrane escape or invasion into surrounding tissue [311]. This early 
heterogeneity suggests there could be additional factors involved in basement membrane 
escape. It is well known that cancer genomes display a decrease in epigenetic regulatory 
marks, except for in CpG rich promoter regions of tumor suppressor genes where 
hypermethylation occurs. Recently, such dysregulation was described in breast cancer 
progression, as well [312]. It is well known that LTR TEs, when deregulated through 
demethylation, drive cell fate and potency as each pluripotent state is linked with the 
activation of distinct classes of TEs [313]. We hypothesize that a change in the LTR 
expression signature plays a role in the cell fate shift of breast tissue transformation to 
metastasis. To test this hypothesis, we aimed to develop a bioinformatics pipeline to 
accurately analyze gene and TE expression from RNA-Seq data derived from formalin-
fixed, paraffin-embedded (FFPE) clinical samples. Next aim is to, identify the genome-
wide retrotransposon expression signature during breast cancer progression. Lastly, we 
aimed to demonstrate that TE expression contributes to the transition from pre-
malignant to malignant breast cancer by altering their repression and mobile activity 
through direct and indirect inhibition of DNA methylation and reverse transcriptase and 
integrase inhibition. 
 
1.5 Significance and Impact on Health 
Current clinical imaging and detection technologies have increased the number of 
diagnoses of very early breast cancer, including atypia (early neoplasia) and ductal 
carcinoma in situ (DCIS). As previously mentioned only one-third of these early 
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diagnosed breast cancer cases will progress into an invasive form. Our current 
understanding lacks the capability to identify early breast cancer diagnoses that will most 
likely transform into invasive carcinoma. Current treatments for individuals diagnosed at 
pre-malignant stages of breast cancer involve breast conserving surgery with radiation 
therapy or a mastectomy. While there are clear benefits to receiving radiation therapy 
with breast-conserving surgery, there are also drawbacks [314]. For example, radiation 
therapy is administered to the whole breast, requires daily treatments, and is associated 
with an increased risk of secondary cancers [315, 316]. Mastectomy is the second most 
likely treatment for DCIS, especially with patients who have a mass of 4-5cm or more 
[317]. Patients who undergo mastectomy have a very low probability of a recurrence. 
However, patients are still at an increased risk of an untreated breast developing DCIS or 
IDC [318]. Some patients who elect for mastectomy have lifelong side effects that 
adversely affects their quality of life, such as phantom pain, fatigue, lymphedema and 
hormonal dysregulation issues. Understanding the mechanisms of breast cancer 
transformation is imperative to treatment and care of the ~80,000 patients diagnosed at 
early stages of breast cancer before IDC each year [319].  
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Chapter Two: 
Bioinformatics optimization of clinical samples 
 
2.1 Introduction 
 After next-generation sequencing was introduced in 2005, many high-throughput 
“next-generation” sequencing (NGS) approaches followed [1]. One of the approaches 
introduced in 2008, RNA sequencing (RNA-seq), captures transcriptomes from 
collections of cells or tissue samples. Reads generated by RNA-seq can then be used to 
assess single nucleotide polymorphisms (SNPs), detect splice variants, detect fusion 
genes, and measure individual transcript abundance in the samples for differential 
expression analysis. Thusly, this exciting technology has since been used for diagnoses, 
prognoses, and therapeutic selections [2-4]. In comparison to previous popular 
technologies, microarrays, RNA-seq provides better transcriptome coverage and is more 
suitable for discovery science, as the identification of expressed genes is not limited to the 
probes present on the array [5, 6]; on the flip side, gene expression analysis becomes 
computationally more challenging due to the requirement to identify each and every read 
output in RNA-seq dataset. However, as NGS technologies and computers able to run the 
analyses have become cheaper, RNA-seq has expanded rapidly producing massive 
amounts of data to be analyzed.  
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 2.1.1 Research Purpose and Approach 
 Many everyday experimentalists and clinicians, who utilize RNA-seq in their 
experiments, rely on outsourcing to cores or companies which generate and analyze their 
RNA-seq data. This practice is common with many niche experiments, particularly omics 
based. The purpose of the research is to bridge the gap between those in the RNA-seq 
niche and the everyday experimentalist or clinician by showcasing the importance of 
understanding biological conditions and the bioinformatics analysis applied. 
For an ideal RNA-seq experiment, researchers and clinicians would require freshly 
frozen tissue samples with minimal contamination from other tissues (e.g. blood, fat). 
However, most clinical research relies on archived tissue samples (formalin fixed paraffin 
embedded, FFPE), or are hindered by limited sample material from biopsy collection. It 
is worth noting that FFPE samples have increased nucleotide degradation and decreased 
poly(A) binding affinity [7-9]. We analyze RNA-seq data from formalin fixed paraffin 
embedded tissue, which is highly variable for quality and depth of reads. We believe the 
quality and depth of these data to represent the quality and depth of data the everyday 
researcher or clinician will likely work with. One of the most common biological question 
asked when analyzing RNA-seq data is, “What genes have different levels of transcription 
in one experimental condition when compared to another experimental condition?” To 
determine differential expression, RNA-seq reads need to be assessed for quality and then 
aligned to a reference genome. 
 After quality control checks, alignment is most often the first step in RNA-seq 
analysis and any analysis thereafter relies heavily upon this initial step. Generally, when 
available and well annotated, reads obtained from sequencing will be mapped to either a 
reference genome or a transcriptome of a species. For simplicity, we will be describing 
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tools and settings for mapping to a reference genome. For in-depth discussion, see a 
recent review by Conesa et al [10]. The biggest challenge for aligning RNA-seq reads to a 
reference genome is that most reads have exon-exon splice junctions. The most common 
software platforms available for mapping to a reference genome, TopHat [11], HISAT2 
[12], and STAR [13], identify splice junctions. Where these platforms differ is 
computationally, with respect to speed and memory usage, and their algorithms for 
handling base and splice junction alignment precision. TopHat is currently not 
maintained and has been superseded by HISAT2 due to computational inefficiencies, 
both of which are built on the short read mapping program Bowtie2 [14]. While all three 
aligners are considered fast, HISAT2 and STAR consistently outperform TopHat with 
respect to computational speed [13, 15, 16]. Baruzzo et al [16] and Engstrom et al [17], 
provide insight into the major differences in aligner performance. All three aligners 
performed well in placing a read onto the respective genomic locus. However, significant 
discrepancies and deficiencies were found for TopHat in getting a read to align or total 
percent mapped. Here we evaluate the alignment performance of STAR and HISAT2 due 
to the discrepancies in TopHat performance in previous comparison papers. 
 The relative expression level of genes is estimated based on the number of mapped 
reads. These counts are subjected to statistical tools to assess significant differences 
between groups. Here we explain and assess the strengths and weaknesses of the two most 
widely used differential expression analysis tools, DESeq2 [18] and edgeR [19]. A 
simplified bioinformatics pipeline for raw data to differential expression analysis can be 
found in Figure 2.1. We performed differential gene expression analysis using the series 
of breast cancer progression RNA-seq data from FFPE samples. In our comparison we 
assessed similarities and differences in the results, to test if (and how) different aligners 
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affect the gene expression level counts or location of mapping, and if different algorithms 
used for assessing differential gene expression affect the “final list” of statistically 
significant transcripts, as well as downstream analysis for Gene Ontology [20] 
enrichment. We focused on two of the most popular aligners, HISAT2 and STAR, and two 
differential gene expression testing tools, DESeq2 and edgeR, all available for users via 
the Galaxy platform, a portal designed to fulfill the bioinformatics needs of researchers 
with very modest bioinformatics and programming experience. 
  
2.2 Methods 
 2.2.1 Breast cancer samples 
 A dataset of 72 RNA sequencing experiments is deposited in NCBI SRA database 
(project number PRJNA205694 [21]). Datasets represent transcriptomes of biopsies from 
different stages of breast cancer: 24 normal tissues, 25 early neoplasia (EN), 9 ductal 
carcinoma in situ (DCIS) and 14 infiltrating ductal carcinoma (IDC), from 25 patients. 
Briefly, RNA was extracted from core punches of FFPE specimens after histological 
confirmation of the cancer stage; only samples that possessed >90% of luminal cells with 
Figure 2.1. Bioinformatics pipeline for RNA-Seq tool analysis (Unpublished) 
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the appropriate diagnosis were used. Directional cDNA libraries were constructed and 
sequenced using Illumina GAIIx to obtain 36-base single-end reads. We used these data 
to compare two common aligners, STAR and HISAT2, and differential expression tools, 
DESeq2 and edgeR (Figure 2.1). 
  
2.2.2 RNAseq reads alignment 
 We used two different programs, STAR and HISAT2, to align the RNAseq reads to 
the reference human genome assembly (hg19). For more precise alignment, both 
programs use a dataset of known splice sites for correct identification of potentially 
spliced reads in RNAseq data; this dataset, in “gene transfer format” (gtf), was obtained 
from ENSEMBL (release 87, 12/8/2016).  
  2.2.2a STAR  
 STAR’s algorithm [13] uses a two-step approach. STAR aligns the first portion, or 
seed, of a read to a reference genome up to the maximum mappable length (MML) of the 
read then aligns the left-over portion, second seed, of the read, up to its MML. After the 
read is completely aligned, STAR stitches the two, or more, seeds together and scores 
them based off a user-defined penalty for mismatches, insertions, and deletions. The 
“stitched” seeds with the highest score are chosen as the correct alignment of a read. This 
approach allows for quick and easy annotation of multi-mapping reads with their own 
alignment scores. --seedSearchStartLmax 50 –seedSearchStartLmaxOverLread 1.0 –
seedSearchLmax 0 –seedMultimapNmax 10000 –seedPerReadMax 1000 –
seedPerWindowMax 50 –seedNonoLociPerWindow 10 –alignIntronMin 21 –
alignIntronMax 0 –alignMatesGapMax 0 –alignSJoverhangMin 5 –
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alignSJDBoverhangmin 3 –alignSpliceMateMapLmin 0 –
alignSplicedMateMapeLminOverLmate 0.66 –alignWindowsPerReadNmax 10000 –
alignTranscriptsPerWindowNmax 100 –alignTranscriptsPerReadNmax 10000 –
alignEndsType Local  
  2.2.2b HiSAT2 
 HISAT2 uses the Bowtie2 [14] algorithm to construct and search a Ferragina-
Manzini (FM) index [22]. However, HISAT2 employs two types of indexes for aligning: a 
whole-genome FM index to anchor alignments, and numerous overlapping local FM 
indexes for extension of the alignment. --mp MX=6, MN=2 –sp MX=2,MN=1 –np 1 –rdg 
5,3 –rfg 5,3 –score-min L,0,-0.2 –pen-cansplice 0 –pen-noncansplice 12 –pen-
canintronlen G,-8,1 –pen-noncanintronlen G,-8,1 –min-intronlen 20 –max-intronlen 
500000 
 
 2.2.3 Gene expression counts 
 The simplest method for estimating transcript expression is to count the raw reads 
for each annotated genomic locus in the genome assembly. This approach uses a gene 
transfer format (GTF) file that contains coordinates (i.e., positions in the genome for each 
exon, transcription start site, transcription termination site, etc.) and nomenclatures of 
genes. We used FeatureCounts [23], a program that extracts information from bam files 
for reads overlapping with features in an input gtf file containing exon coordinates for all 
transcripts in the genome assembly, with the following parameters: --t ‘exon’ –g ‘gene_id’ 
–M –fraction –Q 12 –minOverlap 30. 
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 2.2.4 Data normalization and quality control 
  2.2.4a Data normalization  
 There is much confusion in the literature when reporting units of expression for 
RNA-seq data. The confusion stems from the different forms of normalization required 
for within sample comparison vs between samples comparison. Many methods for within 
sample comparison attempt to correct for sequencing depth and gene length. These 
methods produced the most frequently reported unit of expressions for RNA-seq data, 
which are read per kilobase of exon per million reads (RPKM), fragments per kilobase of 
exon per million of reads (FPKM), and transcripts per million (TPM)[24]. The order in 
which RPKM and FPKM normalize the read counts causes differences within samples that 
should not be ignored. Instead, when comparing within samples one should use TPM 
values which eliminates the invariance within samples[24]. A relationship between 
RPKM/FPKM and TPM is derived here[25]. Alternative normalization methods, which 
allow for comparisons between samples or differential expression analysis, are available 
and explained in the next section. We used CPM normalization of gene count data for 
quality control step using the following formula: 
CPMi = Ri / TRa × 1,000,000  
where CPMi is a CPM value of a gene in a biological replicate; Ri is the number of reads 
mapping to all exons of this gene in this biological replicate; TRa is the total number of 
reads aligned (anywhere in the genome) from this biological replicate (i.e., the number 
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of aligned reads in either STAR or HISAT2 output “binary alignment map” bam files). 
This procedure also transforms data from counts to a continuous scale. 
  2.2.4b Quality control  
 For quality control, we used ClustVis [26], a statistical tool for clustering of 
complex data such as RNAseq, based on principal component analysis and visualization 
of results. Any samples that fell outside of the initial 95% confidence interval on the two-
dimensional PCA plot were flagged as outliers and removed before further analysis. 
ClustVis is an intuitive user interface built on several R packages that provides Principal 
Component Analysis (PCA) and heatmap plots of high-dimensional data from a data 
matrix. Data may be uploaded by a delimited file or copy and pasted into the ClustVis text 
box. Dimensions (e.g. genes) and observations (e.g. samples) may have multiple 
annotations that can be detected automatically or input manually to provide additional 
depth to the PCA and heatmap plots [26]. 
 
 2.2.5 Differential gene expression analysis 
 According to citation reports, edgeR and DESeq2 are the leading tools for 
differential gene expression analysis of RNAseq data (9,411 and 7,318 citations in Google 
Scholar, respectively; retrieved 12/2018). Both tools are R packages and require raw read 
counts in a data matrix which they normalize to account for differences in sequencing 
depth and low count variability. Both tools assume the data will have variance beyond 
what is expected in random sampling, what’s known as overdispersion. Therefore, they 
assume the data will fit a negative binomial distribution and further attempt to shrink the 
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raw counts into this distribution through unique Empirical Bayes methods. To display 
differential expression outputs uniformly we used the R package ViDGER [27]. 
  2.2.5a DESeq2  
 DESeq2 normalizes each gene using a generalized linear model [28]. Then, 
DESeq2 uses an Empirical Bayes shrinkage to detect and correct for dispersion. Unlike 
early versions of edgeR, DESeq2 also uses an Empirical Bayes shrinkage on log2-fold 
change estimates. Within R, the “raw count data” was imported as a matrix along with a 
“DataFrame” that has a column which annotates the columns of the imported matrix. A 
DESeqDataSet was generated with these imported files using the DESEq2 function 
DESeqDataSetFromMatrix(countData=”raw count data”, colData=”DataFrame”, 
design=~0 + Stage). The names in the quotation marks are arbitrary and assigned by the 
user when importing the corresponding files all quotation marks should be removed when 
using the functions in R. The design argument within the function is a formula which 
expresses how the counts for each gene depend on the variables in colData. Here, the 
design formula of ~0 + Stage will build a results table and plot all experimental group 
comparisons. The data was filtered to keep only genes that had at least 4 counts between 
at least 10 samples generating the function keep <- 
rowSums(counts(“name_DESEQDataSetFromMatrix”)>4) >=10 and applying it to 
“name_DESEQDataSetFromMatrix” with name_DESEQDataSetFromMatrix <- 
name_DESEQDataSetFromMatrix[keep,]. The DE analysis was called using 
DESeq(“name_DESEQDataSetFromMatrix”). 
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2.2.5b EdgeR  
 EdgeR’s default method of normalization is called trimmed mean of M-values, or 
TMM, obtained with the function calcNormFactors. This method of normalization 
estimates the ratio of RNA production through a weighted trimmed mean of the log 
expression ratios. There are alternative normalization methods available in edgeR to 
account for data that does not fit the negative binomial distribution assumed with TMM. 
To control for false discovery rate (FDR) we applied the estimateDisp function. 
 
 2.2.6 Gene enrichment analysis using Visual Annotation Display 
(VLAD) 
 VLAD [29], accessible via MGI web portal, is a powerful tool to find common 
functional themes in the lists of genes by analyzing statistical over- or 
underrepresentation of ontological annotations. Currently, users can choose among Gene 
Ontology (GO) [20] annotations for human genes, Gene Ontology and Mammalian 
Phenotype Ontology (MP) [30] annotations for mouse genes, or upload a file of own 
annotations (in open biomedical ontology [31] ‘obo’ format). Unlike other packages for 
ontological enrichment, VLAD allows analysis of more than one query (i.e., several lists 
of genes may be analyzed and visualized simultaneously), as well as permits user to 
provide own “universe set”, i.e. gene list to test queries. For GO analysis, we searched for 
overrepresentation among terms with experimental evidence (i.e., codes EXP, “Inferred 
from experiment”; IDA, “Inferred from direct assay”; IMP, “Inferred from mutant 
phenotype”; TAS, “Traceable author statement”).  
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2.3 Results 
 2.3.1 Output of aligners 
 All reads for all samples were aligned 
to the human genome assembly (hg19). 
Overall, STAR significantly outperformed 
HISAT2 in aligning the FASTQ reads to the 
genome (Figure 2.2). The generally low 
proportion of aligned reads to all input reads 
for both programs is likely due to the quality 
of the libraries, as a significant number of 
input reads were poly(A) sequences, Illumina adapter sequences, and reads 
corresponding to the very 3’-ends of mRNAs, which are too uninformative for correct 
mapping  
  
2.3.2 Quality control 
 To eliminate sample outlier biases, 
we performed Principal Component 
Analysis of gene expression counts for each 
sample by each stage for both aligners. Gene 
expression counts were collected using 
featureCounts and normalized to the total 
number of aligned reads for each sample, and 
PCA completed on these data using ClustVis 
(large edition). For all subsequent analysis, 
Figure 2.2. Performance of HISAT2 and STAR 
aligners on the breast cancer series data. 
(Unpublished) 
Figure 2.3. PCA visualization of gene expression 
data from HISAT2 and STAR alignments. A, B: 
Clustering of HISAT2 samples on the first two principal 
components before (A) and after (B) outlier removal. C, 
D: Clustering of STAR data before (C) and after (D) 
outlier removal. (Unpublished) 
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any samples that fell outside the 95% confidence ellipse in their respective stages 
(Normal, Atypia, DCIS and IDC) were removed. For both HISAT2 and STAR, the same 
samples fell outside of the 95% confidence ellipse in each stage (Figure 3). In total, we 
identified six outlier samples in the RNAseq dataset, which were: SRX286949 (normal 
tissue), SRX286945 and SRX286964 (atypia), SRX286961 (DCIS) and SRX286951 
(IDC). Interestingly, the PCA plots for all stages in HISAT2 data had the Atypia stage 
cluster well removed from other stages (Figure 2.3A & B). Overall, Atypia stage presented 
more heterogeneity than any other stage, irrespective of the aligner. 
  
2.3.3 Gene expression profiling 
  2.3.3a Highly expressed genes  
 To determine how concordant the alignment tools were in mapping the reads to 
the genome, we compared the highest expressed genes that correspond to 50% of all reads 
mapped to exons. In the normal samples, 50% of the mapped reads came from 330 and 
305 genes for STAR and HISAT2 respectively and they shared 263 of those genes (Figure 
2.4). In atypia samples, 50% of the mapped reads came from 417 and 406 genes for STAR 
and HISAT2 respectively and they shared 40 of those genes. In DCIS samples, 50% of the 
exon-mapped reads came from 469 and 416 genes for STAR and HISAT2, respectively; of 
Figure 2.4. Overlap between the highest expressed genes in the RNAseq breast cancer datasets aligned 
by HISAT2 or STAR. HISAT2-identified genes are in red; STAR genes are in green; overlapping genes are in 
yellow. (Unpublished) 
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those, 383 genes were shared. In IDC samples, 50% of the exon-mapped reads came from 
384 and 366 genes for STAR and HISAT2, respectively, and the lists shared 319 of those 
genes. The high amount of discrepancies in atypia convinced us to look further into what 
were the major differences in alignment. 
 2.3.3b Alignment to pseudogenes.  
Retrogenes are intronless gene 
copies produced by reverse transcription of 
a “parent” gene mRNA and insertion of the 
cDNA copy elsewhere in the genome. 
Retrogenes are often non-functional and are 
generally assigned to the category of 
“pseudogenes”, i.e. genomic loci harboring 
similarity to a protein-coding gene but not 
having any recognized function. The 
sequence similarity among retrogenes and 
their parent genes poses a problem for 
aligners, whose algorithms must decide 
when assigning a read to a specific locus in the 
genome. To determine what the differences in 
alignments were, we analyzed the numbers of 
reads mapped to pseudogenes by HISAT2, and STAR. Between two aligners tested, 
HISAT2 consistently had significantly higher amounts of reads aligned to pseudogenes 
when compared to STAR (Figure 2.5A). Furthermore, for Atypia stage, HISAT2 had 
drastically higher amounts of reads aligned to pseudogenes than the other stages. To 
Figure 2.5. Expression of retrogenes in HISAT2 
and STAR alignment data. A: Proportions of all 
reads, by stage, aligned to annotated pseudogene 
loci by HISAT2 (red) and STAR (green). B: Number 
of retrogenes among highest-expressed genes by 
stage, and aligner. (Unpublished) 
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determine what portion of the top 50% of mapped reads were pseudogenes, we obtained 
a list of pseudogenes from the hg19 gtf annotation file we used and compared this list with 
the top 50% of mapped genes for each stage and each aligner. A single pseudogene was in 
the gene list for each stage which represented the top 50% of mapped reads for STAR. 
Conversely, HISAT2 consistently had higher amounts of pseudogenes represented in the 
top 50% of mapped reads (Figure 2.5B). 
  
2.3.4 Differential gene expression analysis 
 The differential expression comparison on data from different alignment tools was 
done to further explore the consequences of previously described alignment tool biases, 
as well as to compare the two popular tools used for the purpose of identification and 
quantification of gene expression differences between different conditions, edgeR and 
DESeq2. 
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Figure 2.6. MA plots of pairwise comparisons of all stages. A. edgeR. HISAT2 (top) and STAR (bottom). B. 
DESeq2. HISAT2 (top) and STAR (bottom) gene counts for all samples were analyzed to identify differentially 
expressed genes. Each gene is represented by a single dot. Blue dots represent genes whose expression 
difference between conditions is both significant and at least two-fold. Green dots represent genes whose 
expression difference between conditions is significant, but less than two-fold; grey dots represent genes whose 
expression differences between conditions is not statistically significant. Y-axis (all plots): log2 of expression fold 
change; X-axis (all plots): log of gene expression mean value. (Unpublished) 
A 
B 
78 
 
2.3.4a edgeR of HISAT2 and STAR bams  
Overall patterns of differential gene 
expression performed by edgeR on HISAT2 
and STAR data were similar for all pairwise 
stage comparisons, except atypia vs any 
other stage (Figure 2.6). HISAT2 
consistently had the atypia stage 
comparisons produce > 15,000 statistically 
significant differentially expressed 
transcripts with a log2 fold change (LFC) ≥ 1 
(i.e., difference in expression between 
condition is at least two-fold) (Figure 2.7). Conversely, differential expression pairwise 
comparisons with STAR atypia stage vs each other stage identified 350 to 2,496 
differentially expressed genes (Figure 2.7).   
  2.3.4b DESeq2 of HISAT2 and STAR bams  
 Differential expression analysis using DESeq2 on pairwise comparisons of STAR 
alignments Normal vs Atypia revealed 255 transcripts having LFC > 1 and 177 transcripts 
with LFC < 1. Normal vs DCIS and Normal vs IDC analysis revealed 1,677 LFC > 1, 482 
LFC < 1, and 2,304 LFC > 1, 1,417 LFC <1 DE transcripts, respectively (Figure 2.6B, 
bottom panels). Similarly, to edgeR differential expression analysis of HISAT2 with 
DESeq2 consistently produced high numbers of DE transcripts in atypia pairwise 
comparisons, > 19,000 transcripts with LFC > 1 (Figure 2.6B, top panels). Normal vs 
Atypia, Normal vs DCIS, and Normal vs IDC analysis revealed 19,419 LFC > 1, 1,212 LFC 
Figure 2.7. Numbers of differentially expressed 
genes in pairwise comparisons, by aligner (HISAT2 
or STAR), and quantification program (edgeR or 
DESeq2). (Unpublished) 
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< 1, 1,585 LFC > 1, 190 LFC < 1, and 2,196 LFC > 1, 732 LFC < 1 DE transcripts, 
respectively.  
2.3.4c Comparison of DESeq2 and edgeR results  
 To compare how similar the most common differential tools, edgeR and DESeq2, 
are on the same aligners we produced Venn diagrams of all DE genes each produced, for 
each pairwise cancer stage comparison to normal samples. DESeq2 and edgeR shared 
341, 1,678, and 2,809 of the differentially expressed transcripts on the STAR alignment 
pairwise comparisons for Normal vs Atypia, Normal vs DCIS, and Normal IDC, 
respectively (Figure 2.8). DESeq2 and edgeR shared 14,220, 1,433, and 2,137 of the 
differentially expressed genes on the HISAT2 alignment pairwise comparisons for 
Normal vs Atypia, Normal vs DCIS, and Normal vs IDC, respectively.  
 
 
 
Figure 2.8. Overlap of genes identified as differentially expressed. Top row is HISAT2-aligned data. Bottom 
row is STAR-aligned data. (Unpublished) 
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2.4 Discussion 
STAR had the highest average rates of mapped reads for each stage. Conversely, 
HISAT2 not only had lower rates of alignment but also had increased rates of pseudogene 
alignment which may have compromised alignment fidelity. We recommend STAR 
alignment over this version of HISAT2. It’s important to note that no alignment tool is 
right for every job and that alignment parameters play a large role in alignment outcomes. 
For in depth explanations and comparisons of aligners we refer the reader to [16, 17]. 
Next-generation technology has improved greatly in a short amount of time. 
Initially, read lengths being generated were between 25 – 36 nucleotides. Currently, 
nucleotide reads can be generated at a length of >300 nucleotides. Chhanawala et al [32] 
reported reads with a length of >25 nucleotides had negligible differences with differential 
expression detection. Conversely to what was previously reported, we believe the short 
nucleotide sequences (36nts) may have been an issue for the FM index generation utilized 
by this version of HISAT2 with the annotated settings, thus propagating misalignments 
to pseudogenes. However, further testing needs to be done to verify. To improve 
concordance between aligners we recommend ensuring greater read lengths during 
experimental design to increase alignment accuracy. 
Recently, Schurch et al [33] compared the performance and accuracy of the top 11 
differential tools available for RNA-Seq analysis. DESeq2 and edgeR out performed other 
tools with the lowest FDR and highest true discovery rate (TDR). Further, they report 
DESeq2 slightly outperformed edgeR with respect to FDR when there were more than 12 
biological replicates. Here, we report DESeq2 having a higher number of significantly 
differentially expressed genes. This may be counter to earlier reports of edgeR’s 
propensity to a higher FDR at higher number of biological replicates. The addition of the 
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estimateDisp function may have applied heavier weighted likelihood empirical Bayes 
methods to obtain the posterior dispersion estimates [34]. Therefore, when dealing with 
higher number of replicates we recommend using DESeq2 or edgeR with the 
estimateDisp function to control FDR. When dealing with lower than 12 replicates we 
believe edgeR and DESeq2 are both viable options however we recommend edgeR as it 
may have an edge in false negative rates (FNR), or TDR. 
These data clearly demonstrate the need for careful considerations and purposeful 
intent when generating and utilizing a bioinformatics pipeline to assess differential 
expression of clinically applicable RNA seq runs. Due to the increase use of RNA seq to 
diagnose, prognose, and generate therapeutic options we feel that clinicians and everyday 
experimentalists should have a strong foundation and understanding of the 
bioinformatics tools being utilized to generate and analyze their data. This study 
highlights possible limitations of this version of HISAT2 for older RNA seq read 
generation technologies, poor quality sample reads, and short RNA seq reads. Thus, 
providing clinicians with insights into the “right” tool for the job. 
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Chapter Three: 
TE & Transcript Analysis of Clinical Samples & in vitro Cell Line Model 
 
3.1 Introduction 
Etiology of breast cancer includes two major, independent, cellular decisions: 
establishment of a small population of atypical cells in healthy tissue and malignant 
transformation of ductal carcinoma in situ (DCIS) stage cells into invasive breast 
carcinoma [1]. The pathways and the regulators underlying these cellular decisions are 
currently poorly understood but clearly have genetic, environmental, and age-dependent 
components. Importantly, neither of these cellular decisions is definitive because not all 
healthy breast tissues will develop atypia, nor all DCIS will become deadly breast cancer 
[2-4]. Detection of breast cancer at early, pre-invasive stages greatly increases the odds 
for long-term survival. Early diagnosis of breast cancer often results in unnecessary 
treatment for the majority of women. In fact, a recent prospective study revealed only 5-
30% of cases of atypia will develop aggressive, invasive forms of breast cancer, whereas 
the majority, 75%-95% will not [5]. The absence of diagnostic biomarkers predicting 
invasive ductal carcinoma (IDC) leads to costly, unnecessary treatment [6].  
There is little understanding why some patients diagnosed with atypia and DCIS 
remain cancer-free for years, while in others the disease progresses rapidly to malignant 
invasive ductal carcinoma. A ‘one gene at a time’ approach does not sufficiently predict 
whether an early lesion will become invasive because it is based on genetic markers 
85 
 
associated with developed tumors. For instance, poor prognosis for human breast cancer 
strongly associates with expression and/or mutations in ERα, ERβ, HER2, PR, EGFR, 
BRCA1, BRCA2 and several other genes in malignant IDC. In contrast, the genetic players 
of atypia and DCIS, and their prognostic value, remain unknown. Therefore, considerable 
interest lies among clinical and biomedical research community to identify the gene 
expression changes driving cell fate decisions at the atypia and DCIS stages, which 
ultimately skew the balance to malignant transformation. 
Changes in cell phenotype from normal to atypical to malignant are reflected in 
changes of gene expression, also known as “gene expression signatures”. Large-scale 
studies using microarray and more recently, next-generation sequencing technologies are 
proving useful in defining gene expression signatures of breast cancer progression from 
early atypia to invasive ductal carcinoma. Over the last decade, a large number of 
microarray gene expression studies were conducted to uncover the gene expression 
signature of atypia and DCIS in human patients, mouse models of breast cancer, and 
mouse-human comparisons [7-12]. Cross-comparison of microarray studies performed 
by different research teams often yield little to no overlap [13], leaving the gene expression 
signature of atypia and DCIS elusive. Thus, a fundamental goal of translational 
bioinformatics is identification of early stage expression changes for impending invasive 
breast cancer from biopsies of premalignant atypia and DCIS compared to control (non-
cancerous). 
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3.1.1 Determining Transposable Element Expression During Breast 
Cancer Progression  
The role of dysregulated LTR retrotransposons as mutagenic agents is widely 
known, as accumulation of retrotransposition-induced mutations in critical genes 
contributes to oncogenesis [14]. Retrotransposition is a hallmark of advanced cancer 
driving genome instability [15, 16].  Of note, HERV-K elements have been detected in the 
plasma of people diagnosed with invasive breast cancer [17]. However, it is unknown if 
specific LTR retrotransposons are expressed in the early stages of atypia and DCIS. TEs, 
notably LTRs, expression at early stages indicate the mechanisms driving genomic 
instability in cancer become active quite early in mammary tumor progression. Moreover, 
TE expression is linked to the undifferentiated state of the chromatin from stem cell 
studies, which has been implicated as a driver in cellular transformation and oncogenesis.  
 
3.1.2 Research Purpose and Approach 
The purpose of this research is to investigate, using in silico methods, the 
expression signature of transposable elements during breast cancer progression. We 
hypothesize that transcriptional re-activation of endogenous retrotransposons occurs 
during transformation of atypia and DCIS. To test this hypothesis, we designed a 
Transposon Enrichment Set Analyses (TESA) based on open-source, published tools 
freely available to the scientific and research community. Furthermore, we also measured 
transcript expression from transcriptome data to detect and corroborate known 
oncogenic pathways. 
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3.2 Methods 
3.2.1 Transcript & TESA Pipeline  
Classic bioinformatic pipelines generated to analyze RNA expression rely on a 
reference genome file (.gtf) during the alignment process and a gene annotation file (.gtf 
or .fasta), which specifies the name of the gene for the genomic location from read 
alignment. Here, we generated a unique transposable element annotation file from the 
RepeatMasker program [18]. The RepeatMasker screens DNA sequences for repeats and 
low complexity DNA sequences then outputs a detailed annotation from the query.  The 
annotation file generated from RepeatMasker was then used in a RNA-Seq bioinformatics 
pipeline further explained below (figure 3.1). 
Briefly, RNA-Seq data of biopsies from formalin-fixed, paraffin-embedded breast 
tissue during oncogenic progression were obtained from NCBI’s national database GEO 
DataSets [19]. These datasets were aligned using STAR aligner to human reference file 
hg19. Read summarization of transposable element counts were generated using 
featureCounts [20] with the alignment file generated with RepeatMasker, as mentioned 
Figure 3.1 Transposon Enrichment Set Analyses (TESA) pipeline/workflow. Orange boxes are 
bioinformatic tools. Light blue boxes are output files. Dark blue boxes are input files. (Unpublished) 
88 
 
previously, and transcript counts were generated using an annotation file from 
ENSEMBL. To assess intrasample and intergroup quality raw counts were normalized 
using counts per million, as previously described (Chapter 2). PCA plots were generated 
with the normalized samples and group outliers were identified and removed. The 
normalized count files that fell within the 95% of the confidence interval were further 
processed through DESeq2 to detect differential expression (DE) of TEs and transcripts 
among all stages. Gene ontology terms were then assigned to DE transcripts using VisuaL 
Annotation Display.  
 
3.2.2 Alignment of RNA-Seq Data Obtained from Clinical and Cell Line 
Models Using STAR  
We aligned the raw breast cancer progression data to the human genome reference 
build HG19 using STAR aligner. STAR’s algorithm [21] uses a two-step approach. STAR 
aligns the first portion, or seed, of a read to a reference genome up to the maximum 
mappable length (MML) of the read then aligns the left-over portion, second seed, of the 
read, up to its MML. After the read is completely aligned, STAR joins the two, or more, 
seeds together and scores them based off a user-defined penalty for mismatches, 
insertions, and deletions. The “merged” seeds with the highest score are chosen as the 
correct alignment of a read. This approach allows for quick and easy annotation of multi-
mapping reads with their own alignment scores. --seedSearchStartLmax 50 –
seedSearchStartLmaxOverLread 1.0 –seedSearchLmax 0 –seedMultimapNmax 10000 
–seedPerReadMax 1000 –seedPerWindowMax 50 –seedNonoLociPerWindow 10 –
alignIntronMin 21 –alignIntronMax 0 –alignMatesGapMax 0 –alignSJoverhangMin 5 
–alignSJDBoverhangmin 3 –alignSpliceMateMapLmin 0 –
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alignSplicedMateMapeLminOverLmate 0.66 –alignWindowsPerReadNmax 10000 –
alignTranscriptsPerWindowNmax 100 –alignTranscriptsPerReadNmax 10000 –
alignEndsType Local 
 
3.2.3 Quality Control Procedure  
To detect and ultimately eliminate outliers of the normalized count files produced 
from the featureCounts program we utilized ClustVis. This tool is a web graphical 
interface built on many R packages that produces Principal Component Analysis plots 
from a data matrix. The tool can handle high dimensional data with many ways to input, 
such as copy and paste or upload [22].  
 
3.2.5 Differential Expression Analysis – DESeq2 
DESeq2 is an R package that requires raw counts in a data matrix. The program 
normalizes the raw counts through a general linear model to account for differences in 
sequencing depth [23]. DESeq2 assumes the normalize counts fit a negative binomial 
distribution, then adjusts the distribution through unique Empirical Bayes methods to 
account for low count variability. DESeq2 also uses Empirical Bayes on log-fold change 
estimates to reduce false positives [24].   Within R, the “raw count data” was imported as 
a matrix along with a “DataFrame” that had a column which annotates the columns of the 
imported matrix. A DESeqDataSet was generated with these imported files using the 
DESEq2 function DESeqDataSetFromMatrix(countData=”raw count data”, 
colData=”DataFrame”, design=~0 + Stage). The names in the quotation marks are 
arbitrary and assigned by the user when importing the corresponding files all quotation 
marks should be removed when using the functions in R. The design argument within the 
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function is a formula which expresses how the counts for each gene depend on the 
variables in colData. Here, the design formula of ~0 + Stage will build a results table and 
plot all experimental group comparisons. The data was filtered to keep only genes that 
had at least 4 counts between at least 10 samples generating the function keep <- 
rowSums(counts(“name_DESEQDataSetFromMatrix”)>4) >=10 and applying it to 
“name_DESEQDataSetFromMatrix” with name_DESEQDataSetFromMatrix <- 
name_DESEQDataSetFromMatrix[keep,]. The DE analysis was called using 
DESeq(“name_DESEQDataSetFromMatrix”). 
 
3.2.6 VLAD Gene Ontology Analysis of DE Output  
VLAD [25], accessible via MGI web portal, is a powerful tool to find common 
functional themes in the lists of genes by analyzing statistical over- or 
underrepresentation of ontological annotations. Currently, users can choose among Gene 
Ontology (GO) [26] annotations for human genes, Gene Ontology and Mammalian 
Phenotype Ontology (MP) [27] annotations for mouse genes, or upload a file of custom 
annotations (in open biomedical ontology [28] known as ‘obo’ format). Unlike other 
packages for ontological enrichment, VLAD allows analysis of more than one query (i.e., 
several lists of genes may be analyzed and visualized simultaneously), as well as permits 
user to provide own “universe set”, i.e. gene list to test queries. For GO analysis, we 
searched for overrepresentation among terms with experimental evidence (i.e., codes 
EXP, “Inferred from experiment”; IDA, “Inferred from direct assay”; IMP, “Inferred from 
mutant phenotype”; TAS, “Traceable author statement”). Here we analyzed the genes that 
were differentially expressed in the disease state when compared to normal. The output 
settings for VLAD was set to show the top 10 GO term nodes. Additional GO analysis was 
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done on only the shared genes that had significantly differentially expression between all 
three disease stages. 
 
3.3 Results 
3.3.1 Expression of Transcripts Across Cancer Progression   
The number of downregulated, when compared to normal, differentially expressed 
transcripts increased at each stage starting with atypia (224) to DCIS (1026) to IDC 
(1797). The number of upregulated when compared to normal increased at each stage 
starting with atypia (208) to DCIS (1133) to IDC (1923). The number of upregulated genes 
were greater than the number of downregulated genes at each stage except for atypia. All 
three disease states had 71 genes in common that were upregulated and 107 
downregulated. Atypia shared 41 and 23 upregulated genes and 28 and 29 downregulated 
  
    
   
  
     
  
          
   
  
    
   
  
     
   
          
   
Figure 3.2 Venn Diagram of Differentially Expressed Transcripts. The number in each circle 
represents the amount of significant differentially expressed genes between comparisons to normal. 
The overlapping number is the mutual differentially expressed genes between the comparisons. The 
nonoverlapping numbers are the unique differentially expressed genes to the stage A. Increased 
expression. B. Decreased expression. (Unpublished) 
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genes with DCIS and IDC, respectively. DCIS and IDC shared 480 upregulated and 652 
downregulated genes (Figure 3.2). 
 
3.3.2 Expression of All TEs Across Cancer Progression  
The percent of transcriptome made up by TEs varied from each stage. Normal samples 
had ~14% of their transcriptome derived from TEs. Atypia, DCIS and IDC stages had 16%, 
31%, and 24% of their transcriptome derived from TE sequences, respectively (Figure 
3.3). The most abundant TE in the transcriptome was by far SINE Alus, followed by LINE 
L1 elements (Figure 3.3). Differential expression analysis with DESeq2 revealed a total of 
91 TEs were differentially expressed in atypia when compared to normal, 50 upregulated 
and 41 downregulated (Table 3.1). DCIS had 93 DE TEs with 52 downregulated and 41 
upregulated. IDC had 90 DE TEs with 38 downregulated and 52 upregulated (Table 3.1). 
Figure 3.3 Gene transcriptome and TE transcriptome. Total transcriptome represents of all reads 
mapped for each stage. TE transcriptome applies to only the portion of TEs mapped. Labels inside 
the donut charts N, A, D, and I are normal, atypia, DCIS, IDC, respectively. (Unpublished) 
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All three stages had 14 TEs downregulated and 8 TEs upregulated in common. Atypia 
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Differentially Expressed TE Classes in Each Stage vs Normal
DNA Transposon Unknown TE LINE SINE LTR
Figure 3.5 Differentially Expressed TEs. The percent of differentially expressed TEs for each stage 
when compared to normal.  N, A, D, I are normal, atypia, DCIS, IDC, respectively. (Unpublished) 
Figure 3.4 Venn Diagram of Differentially Expressed Transposable Elements. The number in each 
circle represents the amount of significant differentially expressed TEs between comparisons to 
normal. The overlapping number is the mutual differentially expressed TEs between the 
comparisons. The nonoverlapping numbers are the unique differentially expressed TEs to the 
stage A. Increased expression. B. Decreased expression. (Unpublished) 
  
  
  
 
  
 
          
   
  
  
  
 
   
  
          
   
94 
 
shared 6 upregulated TEs and 6 downregulated TEs with DCIS and only 3 upregulated 
TEs with IDC (Figure 3.4). The most differentially expressed TEs are derived from LTR 
retrotransposons (Figure 3.5).   
 
Table 3.1 Differentially Expressed TEs for Each Stage 
Normal vs Atypia TE Differential Expression 
Decreased Expression Increased Expression 
Gene ID mean counts log2fc Gene ID mean counts log2fc 
Arthur1A 88.31144 -1.19761 L1P 0.980082 1.128909 
LTR26 42.94001 -0.84414 MER72B 17.07958 0.916284 
MER9B 3.946216 -0.71463 LTR1B 1557.219 0.902702 
LTR47B 38.77274 -0.70031 MER126 3.376455 0.785418 
MER75A 5.174508 -0.67639 MER65B 73.24935 0.766244 
LTR45B 20.86345 -0.66146 Charlie7a 491.628 0.690044 
LTR31 33.38377 -0.64127 LTR80A 5.056746 0.686491 
MER92A 26.71537 -0.63421 LTR21B 271.0958 0.671783 
MER9a1 5.039478 -0.63007 MLT1H1-int 7.397377 0.660866 
UCON8 1.339151 -0.61849 UCON28a 2.022031 0.633624 
LTR33C 30.45387 -0.60741 L1P4e 6.793599 0.623929 
MER30 3304.641 -0.58869 MER129 0.75144 0.618061 
Kanga1 31.79583 -0.55766 Eulor5A 1.094842 0.587229 
LTR5 11.39286 -0.50638 L1P3b 1.846388 0.582259 
MER4B 126.7963 -0.50568 L1P4b 4.984204 0.578542 
Charlie26a 48.28848 -0.48566 MER34D 5.348247 0.523346 
AluYc3 422.5673 -0.48151 REP522 11.35279 0.516018 
PABL_B-int 26.668 -0.47848 LTR35B 9.102511 0.511705 
MER30B 93.93234 -0.4441 HERVL66-int 6.845766 0.509542 
LTR22A 32.48954 -0.43086 L1M3b 22.152 0.507322 
LTR57 149.023 -0.42003 HERV9-int 54.99825 0.504146 
MLT1G1 317.0708 -0.41623 MER117 474.3747 0.493 
LTR2C 70.10864 -0.40906 MLT1F1-int 5.487104 0.478243 
LTR7Y 13.69006 -0.40684 L1M3d 18.64688 0.477292 
LTR71A 15.19133 -0.39458 PRIMAX-int 11.4911 0.46363 
MamSINE1 30.62804 -0.37619 MER34C_ 16.67257 0.463589 
LTR71B 36.38883 -0.37396 HERVK9-int 23.67049 0.453221 
MER67B 22.97493 -0.36667 MADE1 41.47423 0.441296 
LFSINE_Vert 34.7053 -0.35311 Helitron1Nb_Mam 7.396498 0.438009 
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Table 3.1 Differentially Expressed TEs for Each Stage continued 
Normal vs Atypia TE Differential Expression 
Decreased Expression Increased Expression 
Gene ID mean counts log2fc Gene ID mean counts log2fc 
LTR19C 23.57059 -0.3418 Charlie25 40.98877 0.423518 
MER34A1 36.36152 -0.34042 Charlie13b 8.221666 0.416912 
MER57A-int 117.5749 -0.33519 Charlie13a 16.22747 0.411792 
MLT2B3 137.7282 -0.33277 LTR33B 25.14249 0.397622 
MER4B-int 142.0717 -0.3311 LTR83 17.48438 0.39567 
HERVE-int 64.99913 -0.30938 HUERS-P3-int 30.09348 0.389583 
MER4D1 86.04822 -0.30104 MER61C 110.6387 0.373984 
LTR33 335.7643 -0.28012 HUERS-P3b-int 29.15117 0.366634 
MSTB 583.0843 -0.27168 L1MCc 123.1923 0.359872 
L1MEd 775.946 -0.25511 L1MEg1 24.70014 0.349497 
MLT1F 206.4737 -0.22582 L1M3a 53.65659 0.322185 
MER34A 62.62155 -0.21991 MER115 104.8611 0.321623 
      MER34B-int 58.07753 0.315648 
      PABL_A-int 25.69041 0.312568 
      Kanga1d 22.4711 0.310897 
      L1PA4 387.2464 0.30876 
      MER83 32.36049 0.271639 
      MER20B 105.1399 0.237609 
      LTR50 81.84953 0.23303 
      L1MA8 529.3803 0.217301 
      L1MC1 1290.854 0.168575 
Normal vs DCIS TE Differential Expression 
Decreased Expression Increased Expression 
Gene ID mean counts log2fc Gene ID mean counts log2fc 
Arthur1A 88.31144 -2.09674 LSAU 11.58124 1.715874 
LTR47B 38.77274 -1.35732 MER65B 73.24935 1.186762 
LTR71A 15.19133 -1.24783 LTR1B 1557.219 1.178637 
LTR22B 9.025771 -1.17259 L1P 0.980082 0.812512 
LTR33C 30.45387 -1.09236 LTR54 31.52492 0.800878 
MER136 7.400865 -1.08447 MER117 474.3747 0.785503 
LTR26 42.94001 -1.02994 LTR16D2 5.696531 0.784678 
UCON8 1.339151 -0.84387 REP522 11.35279 0.780176 
MER87B 93.73568 -0.82151 LTR48B 50.26594 0.699477 
Kanga1 31.79583 -0.79467 L1P3b 1.846388 0.696507 
MLT1H1 563.7559 -0.79164 BC200 41.36107 0.688127 
LTR7Y 13.69006 -0.72183 MER57C2 13.24137 0.658465 
MER75A 5.174508 -0.70979 MLT1E1 43.42278 0.653669 
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Table 3.1 Differentially Expressed TEs for Each Stage continued 
Normal vs DCIS TE Differential Expression 
Decreased Expression Increased Expression 
Gene ID mean counts log2fc Gene ID mean counts log2fc 
LTR14C 17.30651 -0.70115 LTR38B 18.4308 0.633847 
LTR14B 32.79084 -0.70005 MER50C 12.59559 0.629959 
MER11A 82.26047 -0.6841 LTR19A 40.4795 0.62591 
LTR31 33.38377 -0.66541 AluYd8 17.5837 0.621454 
LTR77 11.17067 -0.63033 MER72B 17.07958 0.617702 
HERVK3-int 42.23356 -0.61771 MER126 3.376455 0.612485 
LTR45B 20.86345 -0.61327 MER34D 5.348247 0.579943 
HERVK14C-int 29.48786 -0.60785 MLT1H1-int 7.397377 0.579398 
PABL_B-int 26.668 -0.60702 Tigger14a 137.99 0.578615 
LTR2B 64.26932 -0.57812 MER34B-int 58.07753 0.578239 
Ricksha_b 6.586193 -0.56754 LTR45C 95.388 0.569887 
Charlie5 140.7848 -0.56399 MER57D 85.42611 0.569602 
LTR47A 122.1144 -0.56255 UCON28a 2.022031 0.567579 
LTR18B 554.2769 -0.56142 HERV1_LTRc 2.540698 0.5644 
Tigger16a 27.83332 -0.52133 UCON12 0.769677 0.563383 
LTR7 269.9551 -0.52074 L1M3b 22.152 0.556069 
MLT1J 1437.407 -0.50306 AluYk12 15.57561 0.550366 
LTR52 74.46954 -0.50299 HERV3-int 59.02318 0.547919 
LTR71B 36.38883 -0.48756 MLT2C1 91.98793 0.543026 
LTR5A 276.3234 -0.48653 LTR35B 9.102511 0.51087 
MamSINE1 30.62804 -0.48147 MER57E3 7.900197 0.507352 
MLT2B3 137.7282 -0.47711 MLT1A-int 18.54955 0.482331 
HERVE-int 64.99913 -0.46512 LTR54B 79.42418 0.46405 
LTR19C 23.57059 -0.45116 MER66B 52.91956 0.463957 
MER113B 15.63274 -0.44184 FAM 2381.384 0.463382 
LTR16B 29.38154 -0.4357 MLT2D 118.0271 0.453338 
MER74C 15.92237 -0.43204 MER54A 106.9699 0.447586 
MER34A1 36.36152 -0.42523 MER61A 74.20794 0.445774 
Tigger2a 120.1334 -0.4221       
MIRb 9179.493 -0.39734       
MER4D1 86.04822 -0.38151       
MER63C 92.03893 -0.37102       
L1MEg2 52.67794 -0.35629       
THE1D 290.7215 -0.33133       
MER5A1 216.3702 -0.32085       
MER68 171.6801 -0.31175       
Charlie19a 41.869 -0.31096       
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Table 3.1 Differentially Expressed TEs for Each Stage continued 
Normal vs IDC TE Differential Expression 
Decreased Expression Increased Expression 
Gene ID mean counts log2fc Gene ID mean counts log2fc 
Arthur1A 88.31144 -2.22411 MSR1 83.43339 1.459245 
LTR33C 30.45387 -1.43662 LTR10B1 29.21936 1.313723 
LTR47B 38.77274 -1.38331 HERVI-int 25.60405 1.18361 
LTR26 42.94001 -1.19 HERV3-int 59.02318 1.05755 
LTR11 4.407613 -1.09968 LTR12B 59.98547 1.01489 
UCON2 6.113835 -1.02234 LTR35B 9.102511 0.95987 
LTR22B 9.025771 -0.94438 UCON28b 2.305686 0.923133 
LTR14C 17.30651 -0.93774 MER57D 85.42611 0.904658 
Kanga1 31.79583 -0.85578 REP522 11.35279 0.885975 
UCON8 1.339151 -0.76292 MER126 3.376455 0.857979 
LTR31 33.38377 -0.7259 MLT2B4 175.1764 0.806983 
MER136 7.400865 -0.71672 MLT1E1 43.42278 0.731794 
HERVK14C-int 29.48786 -0.71089 L1P3b 1.846388 0.731274 
LTR43B 5.763048 -0.63699 ACRO1 2.914097 0.723884 
LTR18B 554.2769 -0.62973 MamRep4096 119.5002 0.72054 
LTR5A 276.3234 -0.60201 MER117 474.3747 0.704449 
LTR81AB 20.83903 -0.59248 MER72B 17.07958 0.691256 
ORSL-2a 4.846807 -0.55552 LSAU 11.58124 0.665175 
LTR77 11.17067 -0.5368 LTR3B 83.12914 0.633166 
LTR45B 20.86345 -0.53585 LTR48B 50.26594 0.612501 
HAL1-3A_ME 133.1612 -0.51514 MLT-int 19.4105 0.608322 
LTR71B 36.38883 -0.51507 L1P 0.980082 0.590872 
MER57E1 124.6372 -0.50986 LTR89 91.29133 0.57424 
MER11A 82.26047 -0.50613 MER91B 56.85263 0.564587 
MamSINE1 30.62804 -0.48073 MER34B-int 58.07753 0.560957 
HERVE-int 64.99913 -0.44387 Charlie7a 491.628 0.559075 
LTR71A 15.19133 -0.43595 LTR45C 95.388 0.554385 
MER74C 15.92237 -0.43385 MER4A1 209.7975 0.54857 
LTR24B 16.62667 -0.4284 UCON4 13.45696 0.505048 
MER106B 34.97379 -0.42594 SVA_F 177.8978 0.48302 
L1M3f 84.27394 -0.41599 MamGypLTR2c 47.37201 0.474557 
Tigger10 114.5806 -0.40669 MER54A 106.9699 0.467797 
Charlie5 140.7848 -0.39116 LTR66 58.15395 0.460548 
MER34A1 36.36152 -0.3804 LTR10E 26.02065 0.449156 
MER51-int 56.46602 -0.37199 MER63B 273.1816 0.447306 
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Table 3.1 Differentially Expressed TEs for Each Stage continued 
Normal vs IDC TE Differential Expression 
Decreased Expression Increased Expression 
Gene ID mean counts log2fc Gene ID mean counts log2fc 
LOR1b 55.24626 -0.33469 MER113A 135.9744 0.445428 
MSTB 583.0843 -0.25025 Arthur1C 12.71432 0.437378 
SVA_D 170.6297 -0.22132 MER1B 437.3959 0.414795 
      MER31B 73.26301 0.412004 
      MLT2C1 91.98793 0.401928 
      MER61C 110.6387 0.401604 
      Tigger11a 440.1543 0.399371 
      MER68-int 14.18787 0.38088 
      LTR79 87.83257 0.380088 
      Charlie16a 109.2027 0.374402 
      MER102b 527.5156 0.354318 
      MLT1C 1671.165 0.343778 
      MLT1G 106.6917 0.304594 
      MER6A 97.45217 0.303702 
      MER115 104.8611 0.290959 
      L2c 6367.266 0.233836 
      L1MB5 967.9758 0.163403 
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3.3.3 VLAD Gene Ontology Output 
3.3.3a Examples of Validation of Cancer Pathways  
The top 10 GO molecular functions terms for transcripts that were increased in 
atypia compared to normal centered around transmembrane transported activity (Table 
3.2 and Figure 3.6). In DCIS the GO analysis of transcripts that were increased compared 
to normal revealed terms for not only transmembrane transporter activity, but also 
GTPase binding to include ras GTPase binding and intracellular trafficking (Table 3.2 and 
Figure 3.7). The increased expressed transcripts from IDC had an overwhelming number 
of cellular components GO terms for extracellular pathways. Furthermore, the molecular 
function GO terms for IDC involved cell adhesion, extra cellular matrix constituents, and 
collagen binding, as well as, growth factor binding and protein kinase binding (Table 3.2 
and Figure 3.8). 
Figure 3.6 Top Ten Overrepresented Gene Ontology Terms of Upregulated Differentially 
Expressed Genes in Atypia. A. Biological Processes. B. Cellular Components. C. Molecular 
Functions (Unpublished) 
A 
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Figure 3.6 (continued) Top Ten Overrepresented Gene Ontology Terms of Upregulated 
Differentially Expressed Genes in Atypia. A. Biological Processes. B. Cellular Components. C. 
Molecular Functions (Unpublished) 
B C 
101 
 
 
Figure 3.7 Top Ten Overrepresented Gene Ontology Terms of Upregulated Differentially Expressed 
Genes in DCIS. A. Biological Processes. B. Cellular Components. C. Molecular Functions (Unpublished) 
C 
B A 
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Figure 3.8 Top Ten Overrepresented Gene Ontology Terms of Upregulated Differentially Expressed 
Genes in IDC. A. Biological Processes. B. Cellular Components. C. Molecular Functions (Unpublished) 
A B 
C 
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3.3.3b Examples of Novel Pathways  
For example, GO analysis of DE gene in DCIS and IDC when compared to normal 
produced outputs that reveal genes in the category to “Response to Virus” under the 
biological process hierarchy and under the molecular function hierarchy, genes belonging 
to Interferon Activation Response terms are significantly overrepresented (Table 3.2 and 
Figures 3.7 & 3.8). Additionally, the 2’-5’-oligoadenylate synthetase activity term for 
molecular function is present for both DCIS and IDC, which indicates this pathway is 
upregulated at a precancerous stage before malignancy occurs (Table 3.2 and Figures 3.7 
& 3.8). This is a novel target pathway to inhibit and mitigate cellular transformation to 
malignancy.  
3.3.3c Conserved Transcripts  
A GO analysis of the 71 conserved transcripts that had an increase in expression 
across all stages of cancer compared to normal, revealed many terms associated with 
regulating the differentiation processes, transport activity, and hormone binding.  
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Table 3.2 Top 10 GO Terms of DE Genes for Each Stage Compared to Control 
and Each Category  
Biological Processes 
Atypia DCIS IDC 
TermID Term TermID Term TermID Term 
GO:0060971 
embryonic heart 
tube left/right 
pattern formation GO:0071357 
cellular 
response to 
type I interferon GO:0030198 
extracellular 
matrix 
organization 
GO:0048468 cell development GO:0060337 
type I interferon 
signaling 
pathway GO:0043062 
extracellular 
structure 
organization 
GO:0060562 
epithelial tube 
morphogenesis GO:0034340 
response to 
type I interferon GO:0002376 
immune system 
process 
GO:0060972 
left/right pattern 
formation GO:0046903 secretion GO:0019221 
cytokine-
mediated 
signaling 
pathway 
GO:0030856 
regulation of 
epithelial cell 
differentiation GO:0032879 
regulation of 
localization GO:0046903 secretion 
GO:0008016 
regulation of 
heart contraction GO:0006811 ion transport GO:0032879 
regulation of 
localization 
GO:0006811 ion transport GO:0051179 localization GO:0045055 
regulated 
exocytosis 
GO:1990778 
protein 
localization to cell 
periphery GO:0006629 
lipid metabolic 
process GO:0032940 secretion by cell 
GO:0051239 
regulation of 
multicellular 
organismal 
process GO:0050790 
regulation of 
catalytic activity GO:0051239 
regulation of 
multicellular 
organismal 
process 
GO:0099637 
neurotransmitter 
receptor transport GO:0009615 
response to 
virus GO:0034097 
response to 
cytokine 
Cellular Components 
Atypia DCIS IDC 
TermID Term TermID Term TermID Term 
GO:0005891 
voltage-gated 
calcium channel 
complex GO:0005737 cytoplasm GO:0031982 vesicle 
GO:0097458 neuron part GO:0044444 cytoplasmic part GO:0044421 
extracellular 
region part 
GO:1902495 
transmembrane 
transporter 
complex GO:0031982 vesicle GO:0005615 
extracellular 
space 
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Table 3.2 Top 10 GO Terms of DE Genes for Each Stage Compared to Control 
and Each Category continued 
Cellular Components 
Atypia DCIS IDC 
TermID Term TermID Term TermID Term 
GO:1990351 
transporter 
complex GO:0044425 membrane part GO:0031012 
extracellular 
matrix 
GO:0034704 
calcium channel 
complex GO:0044459 
plasma 
membrane part GO:0005576 
extracellular 
region 
GO:0034702 
ion channel 
complex GO:0016020 membrane GO:0005737 cytoplasm 
GO:0008282 
inward rectifying 
potassium channel GO:0031410 
cytoplasmic 
vesicle GO:0070062 
extracellular 
exosome 
GO:0044459 
plasma membrane 
part GO:0097708 
intracellular 
vesicle GO:1903561 
extracellular 
vesicle 
GO:0098590 
plasma membrane 
region GO:0070062 
extracellular 
exosome GO:0043230 
extracellular 
organelle 
GO:0043005 neuron projection GO:0012505 
endomembrane 
system GO:0044444 
cytoplasmic 
part 
GO:0034703 
cation channel 
complex       
Molecular Function 
Atypia DCIS IDC 
TermID Term TermID Term TermID Term 
GO:0022857 
transmembrane 
transporter activity GO:0001730 
2'-5'-
oligoadenylate 
synthetase 
activity GO:0005515 protein binding 
GO:0005245 
voltage-gated 
calcium channel 
activity GO:0022857 
transmembrane 
transporter 
activity GO:0005201 
extracellular 
matrix 
structural 
constituent 
GO:0005215 transporter activity GO:0016822 
hydrolase 
activity, acting on 
acid carbon-
carbon bonds GO:0008092 
cytoskeletal 
protein binding 
GO:0022843 
voltage-gated 
cation channel 
activity GO:0016823 
hydrolase 
activity, acting on 
acid carbon-
carbon bonds, in 
ketonic 
substances GO:0050839 
cell adhesion 
molecule 
binding 
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Table 3.2 Top 10 GO Terms of DE Genes for Each Stage Compared to Control 
and Each Category continued 
Molecular Function 
Atypia DCIS IDC 
TermID Term TermID Term TermID Term 
GO:0015075 
ion 
transmembrane 
transporter 
activity GO:0017016 
Ras GTPase 
binding GO:0019838 
growth factor 
binding 
GO:0005216 
ion channel 
activity GO:0005515 protein binding GO:0048407 
platelet-derived 
growth factor 
binding 
GO:0022838 
substrate-specific 
channel activity GO:0031267 
small GTPase 
binding GO:0042802 
identical protein 
binding 
GO:0022839 
ion gated channel 
activity GO:0051020 GTPase binding GO:0001730 
2'-5'-
oligoadenylate 
synthetase 
activity 
GO:0022836 
gated channel 
activity GO:0016491 
oxidoreductase 
activity GO:0005518 collagen binding 
GO:0046873 
metal ion 
transmembrane 
transporter 
activity GO:0019899 enzyme binding GO:0019901 
protein kinase 
binding 
GO:0015267 channel activity      
GO:0022803 
passive 
transmembrane 
transporter 
activity      
GO:0015318 
inorganic molecular entity 
transmembrane transporter 
activity       
 
 
3.4 Discussion 
Through in silico methods, we determined that TEs made up a large portion of the 
transcriptome with the highest proportion in DCIS. The highest number of statistically 
significant differentially expressed TEs were LTRs. The highest number of LTRs were 
found to be differentially expressed at the DCIS stage.  
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Conserved transcripts, such as, HOTAIR [29-31], TMEM8A [32, 33], S100A7 [34, 
35], and PAX genes [36-39] had increased expression in disease state compared to 
normal, are known oncogenes. Furthermore, GO analysis revealed oncogenic processes 
and pathways activated before and during the disease state, as well as novel pathways that 
may highlight interesting research to be further explored. Atypia was heavily populated 
with transporter activity GO terms, a hallmark of cancer stem cells [40]. Many of these 
terms were also found in DCIS and IDC. However, DCIS also produced terms involving 
GTPase binding, specifically ras GTPase, a well-known oncogene, and intracellular 
trafficking. Earlier reports of intracellular trafficking dysregulation in DCIS corroborates 
these findings [41].  The diversification of IDC GO terms into well-known oncogenic 
terms, such as, kinase binding, extracellular organization, growth factor binding, cytokine 
signaling, cell adhesion, and collagen binding indicates the invasive nature of the tissues 
sampled.   
Novel pathways include the activity of 2’-5’-oligoadenylate synthetase which is 
known to induce an intrinsic antiviral state [42]. Additionally, many interferon response 
terms are present, which the expression of ERVs are known to induce, followed by an 
antiviral cell state [43-45]. These findings corroborate ERVs being the most differentially 
expressed transposable element and may indicate important implications in the role 
ERVs are playing in breast cancer progression.  
Therefore, we have demonstrated a TE signature during breast cancer progression 
at the early stages, which indicates LTRs as the most abundantly differentially expressed. 
Furthermore, interferon responses as indicated VLAD GO analysis of abundant 
differentially expressed coding regions corroborates LTR endogenous retroviral activity, 
which was further substantiated in previous studies.     
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Chapter Four: 
Regulation of Retrotransposon Activity in an In Vitro Model 
 
4.1 Introduction  
Transposable elements make up ~45% of the human genome. Interestingly, 
retrotransposons, a subgroup of transposable elements, make a larger portion of the 
human genome than protein coding genes. They are mobile genetic elements which can 
insert themselves into other genomic locations using a copy and paste mechanism, as 
reviewed in chapter 1. If left unchecked, the retrotransposition of these elements may 
become deleterious and hinder host survival. The role of retrotransposons as a mutagenic 
agent is well known and the accumulation of retrotransposon-induced mutations in 
important genes contributes to oncogenesis [1, 2]. One of the first lines of defense against 
retrotransposon activity is DNA methylation[3-7]. Along with other epigenetic repressive 
and posttranscriptional mechanisms these host defenses are quite effective[8-10]. 
However, because of the copy and paste mechanisms utilized by retrotransposons, our 
genome is riddled with multiple repeats of identical or highly homologous inserts. A 
recent study, using genome-wide microarray approaches that measured DNA 
methylation changes in cancerous tissue compared to adjacent normal tissue, found that 
disease tissue had highly variable disruption of epigenetic control. Specifically, certain 
members of transposon families, such asSVA, HERV, LINe-1-P, ALU, and MaLR, had a 
loss of methylation appeared in a stochastic fashion [11]. Here we attempt to gain insight 
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into the role of retrotransposons contributions to cancerous events by examining 
MCF10A and MCF10DCIS cell lines using pharmacological approaches. 
  
 4.1.1 Testing the Roles of Retrotransposons in the Transformation of 
Pre-Malignant to Malignant Breast Cancer using pharmacological approach 
  4.1.1a Pharmacological approach  
Until further advancements are made in gene targeted therapy to differentiate 
among the numerous copies of transposable elements, alternative approaches must be 
examined. As previously mentioned, TEs are primarily regulated by epigenetic 
mechanisms.  One approach to induce expression of cryptic transcription start sites 
encoded by LTRs is to inhibit methyl group availability or DNMT activity [12]. 
Furthermore, there is experimental evidence that antiretroviral drugs, such as integrase 
inhibitors and reverse transcriptase inhibitors, influences endogenous retrovirus activity 
[13-16].  
  4.1.1b Genetic Engineering Approaches  
The application of genetic engineering to knockout, knockdown, or even 
overexpress genes of interest has revolutionized medical research. Genetic approaches 
utilize DNA sequence targeting techniques to regulate the loci of interest. Unfortunately, 
TEs have multiple locations within the host genome and a sequence targeted approach 
would damage substantial areas of the genome. For example, a single long terminal repeat 
family may have thousands of genomic inserts with the same or very highly similar 
sequences. For example, the LTR that acts as an alternative promoter for ALK [17] and is 
responsible for the transcription initiation of a constituently active isoform found in many 
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cancers [18] has > 1,000 non-redundant and 5,000 redundant locations in the human 
genome (Figure 4.1) [19].    
 
 4.1.2 Research Purpose and Approach  
The goal of this study is to demonstrate TEs role in the transition from pre-
malignant to malignant breast cancer. We hypothesize that retrotransposon TEs 
contribute to the transformation of breast cancer. To test this hypothesis, we utilized 
novel and previously established pharmacological techniques to induce TE expression 
and inhibit classical TE retrotransposition activity in an immortalized breast cell line and 
a breast cancer cell line which has characteristics of an early stage ductal carcinoma. The 
Figure 4.1 Alternative Promoter and Nonredundant Genomic Locations of LTR16B2. A 
Representation of LTR16B2’s alternative promoter activity in between exons 19 and 20 of ALK. B 
Representation of the nonredundant locations of LTR16B2 repeats in the human genome. Each 
blue line on chromosomes are a single repeat of LTR16B2. Adapted from Human Endogenous 
Retrovirus Database, J Paces, 2019, https://herv.img.cas.cz/  
A 
B 
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expected outcomes of this study are the characterization of TE expression via effects on 
proliferation, migration, and anchorage independent growth.   
 
4.2 Methods 
 4.2.1 Cell culture conditions of both cell lines 
MCF10a and MCF10DCIS cells were cultured in DMEM (Gibco, 316000-034) with 
5% horse serum (ATCC 30-2040), EGF (Sigma, E9644) at 20 ng/ml, hydrocortisone 
(Sigma, H0888) at 0.5 mg/ml, cholera toxin (Sigma, C8062) at 100 ng/ml, insulin 
(Sigma, I6634) at 10ug/ml, and 1% Penicillin-Streptomycin (Gibco, 15140). Cells used for 
experiments were passaged every 3 to 4 days and at a passage number between 5 to 30, 
the ranges arbitrarily chosen to maintain continuity.   
 
4.2.2 Drugs 
 To reduce methyl group availability and retrotransposon repression we used SAM 
cycle inhibitors 3-Deazanplanocin A (Cayman Chemical Company, 11102), 3-
Deazaadenosine (Cayman Chemical Company, 9000785), and DNMTi 5-Azacytidine 
(Sigma, A2385). To decrease retrotransposon activity, we used integrase inhibitors 
Raltegravir (Sigma, CDS023737) and Elvitegravir (Cayman Chemical Company, 17798), 
and reverse transcriptase inhibitor Azidothymidine (Sigma, PHR1292). Many of our 
drugs used dimethyl sulfoxide (DMSO, Sigma, D4540) as a vehicle.  
  4.2.2a 3-Deazaneplanocin A (DZNEP)  
 In vitro studies revealed DZNEP inhibits S-adenosyl-L-3H-methylmethionine and 
3-thymidine incorporation at concentration of 700 nM (200ng/mL). At concentrations 
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between 500 nM and 1 µM (150 ng/mL and 300 ng/mL) DZNEP also depletes EZH2 and 
inhibits trimethylation of lysine 27 on histone 3 (H3k27) [20, 21].  
  4.2.2b 3-Deazaadenosine (DZA)  
The half maximal inhibitory concentration (IC50) of DZA against S-adenosyl-
homocysteine hydrolase is 4 µM. DZA has unspecific inhibitory activity at concentrations 
near 100 µM [22]. 
  4.2.2c 5-Azacytidine (AZA)  
 At a concentration of 40 µM, AZA replaced ~8% of the cytosines in inhibitory DNA 
resulting in 0.6 – 1.8 nM ranges for DNMT inhibition [23].  
  4.2.2d Raltegravir (RAL)  
 Endogenous retroviral DNA remains in a pre-integration complex with integrase 
after reverse transcription. Integrase snips target DNA at the integration site. Raltegravir 
effectively inhibits HIV integrase and HTLV-1 cell-cell infection at concentrations of 
20nM to 90nM (IC95 at 31±20 nM) [14, 24]. Furthermore, Raltegravir was effective at 
inhibiting HERV-K infection with an IC90 of 0.075 µM [16].  
  4.2.2e Elvitegravir (ELV)  
 Second generation integrase inhibitor has a broad antiretroviral activity and 
inhibits integrase at concentrations of 0.5-5.8 nM [15].  
  4.2.2f Azidothymidine (AZT)  
 Endogenous retroviruses are reverse transcribed from RNA to DNA through their 
own viral protein reverse transcriptase. AZT was shown to inhibit recombinant HIV RT 
at 0.32 ± 0.11 µM concentrations and endogenous retrotransposons at 16.4 ± 4.21 nM [13, 
25, 26].  
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 4.2.3 Cell Viability & Density Dose-Response Curves 
 To determine dosage for future experiments, cell viability and density assays were 
performed. Briefly, 25 x 103 of MCF10A or MCF10DCIS cells were seeded with drug into 
each well of a 24 well plate. All drugs were coded with an alphanumeric nomenclature 
before experiments to keep experimenter unaware of treatment groups. After 48 hours in 
treatment cells were trypsinized and pelleted then media was aspirated. The cell pellet 
was resuspended in fresh media. A 15 µl sample of the resuspension was mixed with 
tryphan blue at a 1:1 ratio and cell viability and density was analyzed using a 
hemocytometer. The experimental design is clarified in the table below. Cell viability was 
determined by dividing the number of live cells by the total number of cells. Cell density 
is the total number of live cells. 
Table 4.1 Cell viability and density dose-response curve experimental design 
Drug Name Drug 
Concentrations 
n of Each Drug 
Concentration 
Vehicle H2O Volume of 10 µl/ml 4 
Vehicle DMSO 10 µM, 100 µM 4, 2 
DZNEP 0.1, 1, 10 µM 2 
DZA 1, 10, 100 µM 2 
5-Azacytidine 1, 10, 100 µM 2 
Elvitegravir 1, 10, 100 µM 2 
Raltegravir 1, 10, 100 µM 2 
Azidothymidine 1, 10, 100 µM 2 
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4.2.4 Scratch Assay 
  4.2.4a Pilot Study  
 To examine growth rates and migration patterns as an indicator of the metastatic 
phenotype we performed scratch/wound healing assays. Pilot studies of the scratch assay 
were done in 24 well plates with each cell line, MCF10A and MCF10DCIS, seeded at 5 x 
104 in cell culture media and allowed to reach confluency. When cells reached confluency, 
a scratch was made down the center of each well with a sterile 200 µl pipette tip. Cells 
were washed and media with treatment was added to labelled wells. Each treatment had 
3 wells in the 24 well plate (Table 4.2). Images were taken at time point 0 and every 6 
hours till the 24-hour time point to analyze area of scratch.   
Table 4.2 Scratch assay pilot study experimental design 
Drug Name Drug Concentration n 
Vehicle H2O Volume of 10 µl/ml 3 
Vehicle DMSO 10 µM 3 
DZNEP 1 µM 3 
DZA 10 µM 3 
5-Azacytidine 10 µM 3 
Elvitegravir 10 µM 3 
Azidothymidine 10 µM 3 
 
  4.2.4b WoundMakerTM   
 To further examine growth rates and migration or migration (drug + Mitomycin) 
alone we performed a wound/scratch assay using the Essen WoundMakerTM, a 96-pin 
wound making tool. Briefly, 25 x 103 cells per well were seeded in cell culture media in all 
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96 wells. After 18hrs in an incubator at 37°C with 5% CO2 the WoundMakerTM was utilized 
to create wounds in all wells. Cells were immediately washed twice with culture media 
(100 µl per well). Drugs labeled in a way to ensure blind experimental settings was applied 
to respectively labeled wells. The 96 well plate was then allowed to equilibrate in an 
IncuCyte® incubator before being imaged for time point 0 and every 6 hours for 24 hours. 
To block proliferation in the WoundMakerTM scratch assay for migration only, confluent 
cells were treated with mitomycin C (10µg/mL) for 2 hours (Table 4.3).  
Table 4.3 WoundMakerTM scratch assay experimental design 
Drug Name Drug Conc. n of Drug Only n of Drug + Mitomycin 
Vehicle H2O Volume of 10 
µl/ml 
6 11/12 
Vehicle DMSO 10 µM 6 11/12 
DZNEP 1 µM 5/6 11/12 
DZA 10 µM 6 12 
5-Azacytidine 10 µM 5/6 11/12 
Elvitegravir 10 µM 5/6 11/12 
Raltegravir 100 µM 6 11/12 
Azidothymidine 10 µM 6 11/12 
 
 4.2.5 Transformation Assay 
 To study the in vitro anti-tumorigenesis effect of integrase and reverse 
transcriptase inhibitors and the tumorigenesis potential of dysregulated epigenome 
induce TE expression through SAM cycle inhibitors and DNA methyltransferase 
inhibition we utilized transformation assays. Transformation assays require cell growth 
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in an anchorage independent way. Non-transformed cells require adequate and 
appropriate cell-matrix interactions, otherwise the undergo anoikis [27]. Anchorage 
independent growth is a hallmark of transformation and is a stringent in vitro assay for 
detecting nonmalignant to malignant transformation. All transformation assays were 
performed according to a previously established protocol [28].  Briefly, the protocol 
requires three layers of cell culture media and agarose in a 6 well cell culture plate. The 
bottom layer is 2ml of 0.6% 2-hydroxyethyl agarose solution (Sigma, A4018) in media. 
The middle layer is a cell-containing layer with 0.3% 2-hydroxethyl agarose solution in 
media. The last layer is a feeder layer of 0.3% 2-hydroxyethyl agarose solution in media 
to provide extended access to nutrients for cells. In treatment wells, the appropriate drug 
dose is added to the cell-containing layer and feeder layer and is further explained below. 
Feeder layers are added once a week. It is recommended that images be taken between 
one and two weeks of growth.  
 Here we plated 2 x 104 cells per well in four 6-well plates for each cell line, MCF10A 
and MCF10DCIS, and treated with respective drug in concentrations (Table 4.4).  
Table 4.4 Transformation assay experimental design 
Drug Name Drug Concentration n of MCF10A n of MCF10DCIS 
Vehicle H2O Volume of 10 µl/ml NA 2 
Vehicle DMSO 10 µM 2 2 
DZNEP 1 µM 2 4 
DZA 10 µM 3 3 
Raltegravir 100 µM NA 3 
Elvitegravir 10 µM 3 4 
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After 10 days a grid template was generated, images were taken with a 10mm lens 
microscope camera at the west, north, east, south, and middle of each well. Colonies that 
had a diameter of 50 µm or more were counted using ImageJ software. 
 
4.3 Results 
 4.3.1 Cell Viability & Density Dose-Response Curves 
 A dose-response curve on viability and density was conducted for each drug to 
determine the minimal effective dose in our cell culture assays using viability and density 
assays. SAM cycle inhibitors DZA and DZNEP doses chosen were 10 µM and 1 µM, 
respectively. At the 10 µM dose DZA had no change in cell viability compared to control 
in both MCF10A and MCF10DCIS cell lines (Figure 4.2A & C). However, at 10 µM, DZA 
in MCF10A cell line had increased cell density when compared to control (Figure 4.2B). 
At the 1 µM dose DZNEP had a slight decrease in cell viability for both cell lines, when 
compared to control, and a deficit in both cell lines for cell density (Figure 4.2). The 
DNMT inhibitor AZA dose chosen was 10 µM. Little to no difference was detected for 1 
µM of AZA treatment when compared to control (Figure 4.3). In contrast, 100 µM 
treatment with AZA resulted in large deficits in cell density and a large decrease in cell 
viability (Figure 4.3 A & C). 10 µM treatment with AZA resulted in no change of viability 
with MCF10A and a slight decrease in viability in MCF10DCIS when compared to control 
(Figure 4.3A & C). However, both cell lines experienced a deficit in density (Figure 4.3B 
& D). Integrase inhibitors ELV and RAL doses chosen were 10 µM and 100 µM 
respectively. ELV at 1 µM showed no real difference in cell viability and highly variable 
results for density for both cell lines. At the 100 µM dose of ELV MCF10DCIS cells had a 
decrease in cell viability and both MCF10A and MCF10DCIS had large deficits in cell 
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density when compared to vehicle (Figure 4.4). Overall, RAL had little change in viability 
and density when compared to control regardless of dose.  Reverse transcriptase inhibitor 
AZT dose chosen was 10 µM. There was little effect on cell viability when compared to 
control for both MCF10A and MCF10DCIS cells line regardless of the treatment dose 
(Figure 4.5). Cell density had varying results for treatment doses. At 1 µM MCF10DCIS 
cells had a much greater density when compared to control (Figure 4.5D). Conversely, at 
100 µM MCF10DCIS cells experience slight decrease in cell density (Figure 4.5D). 
MCF10A cells had a slight increase in density at 1 µM and a slight decrease in cell density 
at 100 µM (Figure 4.5B).    
Figure 4.2 Initial Dose-Response Curve for SAM Cycle Inhibitors. A. MCF10A cell viability for DZA and 
DZNEP doses. B. MCF10A cell density for DZA and DZNEP doses. C. MCF10DCIS cell viability for DZA and 
DZNEP doses. D. MCF10DCIS cell density for DZA and DZNEP doses. Red star indicates doses chosen for 
future studies, not an indicator of significance. (unpublished) 
A B 
D C 
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Figure 4.3 Initial Dose-Response Curve for DNA Methyltransferase Inhibitor. A. MCF10A cell 
viability for AZA doses. B. MCF10A cell density for AZA doses. C. MCF10DCIS cell viability for AZA 
doses. D. MCF10DCIS cell density for AZA doses. Red star indicates doses chosen for future studies, 
not an indicator of significance. (unpublished) 
 
Figure 4.4 Initial Dose-Response Curve for Reverse Transcriptase Inhibitor. A. MCF10A cell 
viability for AZT doses. B. MCF10A cell density for AZT doses. C. MCF10DCIS cell viability for 
AZT doses. D. MCF10DCIS cell density for AZT doses. Red star indicates doses chosen for 
future studies, not an indicator of significance. (unpublished) 
  
A B 
D C 
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4.3.2Scratch Assay 
  4.3.2a Pilot Study  
 To measure migration and growth during treatments to induce TE expression or 
reduce TE activity scratch assays were performed. No significant results were found for 
any of the treatments in either cell line until the 24-hour time point. At 24 hr post-stratch, 
AZA and DZNEP had significantly less wound healed when compared to their vehicle 
controls in MCF10A cell line. Nonsignificant increases of wound healing were seen in 
MCF10DCIS cell lines for AZT, ELV, DZA, and AZA. 
 
 
 
Figure 4.5 Initial Dose-Response Curve for Integrase Inhibitors. A. MCF10A cell viability for ELV and 
RAL doses. B. MCF10A cell density for ELV and RAL doses. C. MCF10DCIS cell viability for ELV and 
RAL doses. D. MCF10DCIS cell density for ELV and RAL doses. Red star indicates doses chosen for 
future studies, not an indicator of significance. (unpublished) 
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Figure 4.6 Pilot Study of Wound Assay for MCF10A cell line. A.  SAM cycle inhibitors DZA and DZNEP. 
B. DNMTi AZA C. Integrase inhibitor ELV. D. Reverse transcriptase inhibitor AZT. (unpublished) 
Figure 4.7 Pilot Study of Wound Assay for MCF10DCIS cell line. A.  SAM cycle inhibitors DZA and 
DZNEP. B. DNMTi AZA C. Integrase inhibitor ELV. D. Reverse transcriptase inhibitor AZT. (unpublished) 
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4.3.2b WoundMakerTM 
 To confirm and extend pilot study results, we performed WoundMakerTM scratch 
assays with drug treatment only. For MCF10A cells at 6hrs after the wound was generated 
and treatment was applied only AZA had significant results when compared to control 
with a decrease in the amount of wound healed (Figure 4.8B). AZA continued to have 
significantly less amount of wound healed compared to vehicle control at each time point. 
DZNEP also had significantly less wound healed when compared to vehicle control for all 
time points except 6hrs (Figure 4.8A & B). ELV and DZA had significantly less wound 
healed at 12 hours when compared to control (Figure 4.8A & C). For MCF10DCIS cell line 
no significant difference was determined for any drug treatment at 6-hour timepoint. At 
all other timepoints only AZA had significantly less wound healed when compared to 
control (Figure 4.9B).  
 To determine migration only effects we performed WoundMakerTM scratch assay 
with drug treatment + mitomycin treatment. In MCF10A cells, AZA had significantly less 
migration at each timepoint when compared to vehicle control (Figure 4.10B). AZT had 
nonsignificant increases in migration for the 6-hour and 12-hour timepoint (Figure 
4.10E). In MCF10DCIS cells, again only AZA had significantly less migration when 
compared to control at each timepoint (Figure 4.11B). Starting from 12 hours through 18 
hours, RAL had significantly less migration when compared to control (Figure 4.11D).   
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Figure 4.8  WoundMaker
TM
 Scratch Assay for MCF10A cell line. A.  SAM cycle inhibitors DZA 
and DZNEP. B. DNMTi AZA C. Integrase inhibitor ELV. D. Integrase inhibitor RAL. E. Reverse 
transcriptase inhibitor AZT. (unpublished) 
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Figure 4.9  WoundMaker
TM
 Scratch Assay for MCF10DCIS cell line. A.  SAM cycle inhibitors 
DZA and DZNEP. B. DNMTi AZA C. Integrase inhibitor ELV. D. Integrase inhibitor RAL. E. 
Reverse transcriptase inhibitor AZT. (unpublished) 
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Figure 4.10  WoundMaker
TM
 Scratch Assay Migration Only for MCF10A Cell Line. A.  SAM 
cycle inhibitors DZA and DZNEP. B. DNMTi AZA C. Integrase inhibitor ELV. D. Integrase inhibitor 
RAL. E. Reverse transcriptase inhibitor AZT. (unpublished) 
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Figure 4.11  WoundMaker
TM
 Scratch Assay Migration Only for MCF10DCIS Cell Line. A.  SAM 
cycle inhibitors DZA and DZNEP. B. DNMTi AZA C. Integrase inhibitor ELV. D. Integrase inhibitor 
RAL. E. Reverse transcriptase inhibitor AZT. (unpublished) 
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 4.3.5 Transformation Assay 
 To determine anchorage-independent growth during treatments to induce TE 
expression or reduce TE activity, transformation assays were performed. No significant 
differences were found for any of the treatments when compared to control for MCF10A 
cells (Figure 4.12). In MCF10DCIS cells, DZNEP had significantly fewer colonies with a 
diameter of 50 µm or more when compared to control (Figure 4.13).  
 
Figure 4.12 Transformation Assay for MCF10A Cell Line. A.  SAM cycle inhibitors DZA and 
DZNEP. B. Integrase inhibitor ELV. (unpublished) 
Figure 4.13 Transformation Assay for MCF10DCIS Cell Line. A.  SAM cycle inhibitors DZA and 
DZNEP. B. Integrase inhibitor ELV. (unpublished) 
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 Table 4.5 Results Summary for MCF10A. Outcomes are based on treatment 
compared to vehicle controls. ND no significant difference, NA not available, ↑ increased 
percent of wound healed, ↓ decrease percent of wound healed. 
Treatment Wound Healing 
(Pilot) 
Wound Healing 
(WoundMaker®) 
Wound Healing 
(WoundMaker® + 
Mitomycin C) 
Transformation 
DZA ND 12hr↓ ND ND 
DZNEP 24hr↓ ≥12hr↓ ND ND 
AZA 24hr↓ ↓ ↓ NA 
ELV ND 12hr↓ ND ND 
RAL NA ND ND NA 
AZT ND ND ND NA 
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Table 4.6 Results Summary for MCF10DCIS. Outcomes are based on 
treatment compared to vehicle controls. ND no significant difference, NA not available, 
↑ increased percent of wound healed, ↓ decrease percent of wound healed. 
Treatment Wound Healing 
(Pilot) 
Wound Healing 
(WoundMaker®) 
Wound Healing 
(WoundMaker® + 
Mitomycin C) 
Transformation 
DZA ND ND ND ND 
DZNEP ND ND ND ND 
AZA ND ≥12hr↓ ↓ NA 
ELV ND ND ND ND 
RAL NA ND 12hr, 18hr ↓ ND 
AZT ND ND ND NA 
 
4.4 Discussion 
 These studies tested the role of retrotransposons in breast cancer progression 
using pharmacological approaches and classic invasive and metastasis analysis assays. 
Counter to our expected outcomes for DNMTi AZA, the drug consistently caused 
significantly more cell death and decreased invasiveness when compared to control. 
Additionally, SAM cycle inhibitor DZNEP consistently had significantly less migration in 
MCF10A cells and less anchorage independent growth in MCF10DCIS cells.  While 
initially unexpected, these data corroborate recently published research. In 2015, Hurst 
and Magiorkinis speculated that endogenous retroviruses activate the innate immune 
response [29]. Later studies confirmed this and further determined the inhibition of DNA 
methylation induced an interferon response due to endogenous retroviral expression 
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[30]. I believe future studies with smaller doses of our DNA methylation disruptors may 
further determine roles of retrotransposon expression in breast cancer progression by 
allowing an increase in retrotransposon expression below the threshold necessary to 
induce the innate immune response.  
The nonsignificant increase in migration for MCF10A cells, when treated with the 
reverse transcriptase AZT, is worth further exploration as it may suggest alternative 
activities of RNA transcripts for retrotransposons. Conversely, the integrase inhibitor 
RAL’s anti-migratory results may suggest a decrease in genomic destabilization prevents 
metastatic progression. A decrease in genomic instability upon inhibition would support 
the classic transposon activity in cancer model. Additional soft agar assay experiments 
should be performed to further address trends not significant. 
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Chapter Five: 
Perspectives 
 
5.1 Pipeline for the Common Clinical RNA-Seq Dataset 
 With the introduction and advancement of next-generation sequencing, biologists 
and clinicians have made an enormous amount of discoveries in a short amount time 
when compared to classic sequencing approaches. These next-generation sequencing 
tools produce massive amounts of data and require special attention to their analysis 
because of the potential effects of biological sample preparation, method of sequencing, 
and questions of interest. An ideal translational experiment would involve fresh, or 
freshly frozen, tissue samples micro-dissected from non-target tissues, immediately 
prepped and sequenced. However, circumstances for clinicians and many biologists 
working with specimens from human patients must rely on preservation methods, such 
as, formalin fixed paraffin embedded (FFPE) tissue. These methods of preservation have 
been known to increase nucleotide degradation [1-3].  
 Presented in this thesis, the analysis and comparison of common bioinformatics 
tools study proved successful in the generation of a pipeline that is well-suited for low-
quality, short nucleotide sequence reads data. As described in Chapter 2, this study 
started by examining two common alignment tools, HISAT2 and STAR, to analyze RNA-
Seq datasets derived from FFPE tissue samples. We further developed the pipeline by 
comparing the two most common and robust differential expression analysis tools, edgeR 
and DESeq2. We were able to discover that the version of HISAT2 used in the comparison 
136 
 
had significantly less reads mapped to the human genome. Furthermore, the reads 
aligned by HISAT2, were assigned to pseudogene loci instead of genes, which may 
indicate compromised alignment fidelity in preserved specimens that degrade 
nucleotides. During the comparison of the differential expression tools, DESeq2 and 
edgeR programs yielded similar results although it appears that edgeR’s estimateDisp 
function had increased FDR correction for datasets with 12 or more replicates.  
 Many clinical and experimental laboratories often have their RNA-Seq samples 
brought to a core or commercial analytics company for processing and analysis without 
knowing the pipeline utilized on their data. Equivalently, many bioinformaticians process 
RNA-seq read output without knowledge or understanding of the experimental 
preparations executed at the clinician’s or experimentalist’s laboratory that can bias 
sequencing output. Our study provides evidence that no single bioinformatics tool is 
appropriate to apply to all experiments. Furthermore, parameters setting contribute to 
outcomes for both mapping to a reference genome and measuring differential expression. 
The studies support for STAR aligner to obtain the most robust, accurate alignment for 
RNA-Seq data generated from FFPE samples. Furthermore, we recommend either 
DESeq2 or edgeR if estimateDisp function is applied for studies with 12 or more replicates 
and edgeR without estimateDisp function applied for studies with less than 12 replicates.        
 
5.2 Novel In Silico Method for the Discovery of TE Expression in Breast 
Cancer Progression  
 For decades it has been widely accepted that early pre-malignant breast cancer is 
a precursor to the invasive form. Yet, there is little knowledge as to distinguish the cohort 
of patients diagnosed with pre-malignant breast cancer that never progress to the invasive 
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form. Few advances have been made in the evolutionary bottleneck theory of “one gene 
mutation at a time” until a selected clone escapes the basement membrane.  As previously 
mentioned, a recent study using advanced single cell spatially resolved next-generation 
sequencing provided evidence that clonal selection occurs before tumor cells escape the 
basement membrane, subclones are derived from the same or a similar parent population, 
and multiclonal migration occurs. Early heterogeneity and multiclonal escape suggest 
there could be additional factors involved in basement membrane escape.  
 After optimizing the bioinformatics pipeline tools, breast cancer progression RNA-
Seq data were analyzed to determine the TE expression signature. This analysis revealed 
that the LTR retrotransposons family, ERV expression was the most differentially 
expressed TE at each stage of breast cancer when compared to normal. Additionally, DCIS 
had the highest percentage of TEs differential expressed at ERV genomic regions 
compared to the percent of DE ERVs in other stages.  
 Interestingly, when gene coding regions were analyzed for differential expression 
and gene enrichment analysis with gene ontology terms the outputs revealed interferon 
responses and antiviral activity starting at the DCIS stage. These data corroborate the 
higher percentage of ERVs differentially expressed in DCIS. Furthermore, our transcript 
analysis revealed progressive diversification of GO terms associated with metastasis from 
atypia to IDC. This in silico study provides a foundation of evidence for TE, specifically 
ERV, involvement in breast cancer progression from pre-malignant to malignancy. 
However, replicate findings in silico analysis of RNA-seq data from other independently 
collected specimens and experimental evidence are needed to substantiate our 
discoveries. 
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5.3 Regulating Retrotransposon Expression and Activity Effects on MCF10A 
and MCFDCIS Cell Line Models 
 This study provides convincing introductory data for a role of retrotransposons in 
breast cancer progression. Retrotransposition induced genetic instability is a hallmark of 
advanced cancers [4]. HERV-K particles have been discovered in the plasma of patients 
diagnosed with invasive breast cancer. An important regulator and repressor of 
retrotransposon expression is DNA methylation and other epigenetic mechanisms. 
Previous microarray studies postulate epigenetic dysregulation at retrotransposon loci in 
cancerous tissue when compared to adjacent normal tissue. This study examines the role 
of retrotransposons in the establishment of metastatic phenotypes of breast cancer using 
MCF10A and MCF10DCIS cell lines as a model of progression.   
Using a pharmacological approach, the contribution of retrotransposon expression 
to metastatic phenotypes was examined, such as increased migration and anchorage 
independent growth, by treating with DNA methylation disruptors and retroviral reverse 
transcriptase and integrase inhibitors. Our results indicate DNA methylation inhibitor 5-
Azacytidine (AZA) consistently significantly decreased and retarded cell migration and 
growth. These results are not caused by toxicity because cell viability assays showed 
MCF10DCIS cells with decreased viability only at doses higher than used for these 
experiments. While these findings were unexpected; they corroborate a few recent 
studies. In 2015, a paper reported the possibility that ERVs contributes to an increase in 
the innate immune response. That same year it was found that AZA induced an interferon 
response in cancer by depressing ERV expression. These studies have provided data 
supporting the possibility of using AZA, and other epigenetic deregulators, as a 
therapeutic option. Within the last year several studies have started testing known 
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epigenetic deregulators to induce ERV expression beyond a threshold of tolerance, for a 
“viral mimicry”, and initiate an immunotherapy response [5-7]. It’s important to note that 
these studies are providing evidence of an ERV expression threshold to induce immune 
response. These do not discount or discredit the diverse roles TEs play in oncogenesis as 
determined from prior studies [8-16].  The significant mitigation of migration on 
MCF10DCIS cells when treated with an integrase inhibitor RAL corroborates the 
contribution of insertional mutagenesis to advanced cancers. However, further 
pharmacokinetic studies must be performed to determine ERV activity and ensure the 
significant decrease isn’t due to cellular toxicity. Many of the drugs at the doses chosen 
did not produce significant differences. Additional dose-dependent response curve 
studies should be done to explore effective concentrations. 
A major limitation to this study is in the time of exposure during the wound healing 
assays. Drug induced expression of transposable element insertional mutagenesis may 
require weeks of treatment exposure to ensure oncogenic clonal selection occurs. 
Likewise, pretreatment may also provide insight into how TEs drive transformation, 
whether through classical TE mutagenesis or alternative TE activities, like alternative 
promoter exaptation driving oncogenes. To overcome this limitation further experiments 
with pretreatments for 1 to 2 weeks in drug may be performed. Additional limitations 
include the current spectrum of doses tested, the number of transformation assays 
completed, the lack of RNA-seq data for cell line models concordance with clinical RNA-
seq data, and the lack of direct experimental evidence to suggest transposable activity is 
driving transformation. 
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5.4 Future Directions 
 5.4.1 Transposable Element Expression in Breast Cancer Cell Lines 
 The use of MCF10A cell line and its derivations of cancer cell lines as a model for 
breast cancer progression has been extensively studied [17-20]. However, little is known 
as to its concordance of transposable element expression during MCF10A transformation 
and derived cancer lines with clinical samples of breast cancer progression. Therefore, it 
is imperative to determine the TE expression profile of the specific cell lines we use as 
models of oncogenic phenotypes during TE dysregulation and TE activity inhibition. 
   
 5.4.2 Activity of Transposable Elements 
 The use of pharmaceuticals within a dose range known to induce TE expression or 
inhibit TE activity to measure metastatic potential is necessary. However, it is imperative 
these studies be done in conjunction with studies that can measure activity of 
transposable elements. One such approach is the reverse transcriptase activity assay. 
Briefly, purified bacteriophage MS2 RNA are incubated with cell lysate aliquots. Mixtures 
are exposed to PCR amplification using MS2-specific primer pairs to determine if MS2 
cDNA sequences were synthesized. The presence of amplified MS2 cDNA is a measure of 
reverse transcriptase activity.  The assay is roughly based on the protocol established by 
Voisset et al., 2001 [21]. Versions of the assay have previously described endogenous 
reverse transcriptase activity in preimplantation embryos and cancer [22, 23].  
 
5.4.3 Patient-Derived Xenograft Models 
 Patient-derived tumor xenograft (PDX) mouse models offer a unique translational 
prospect for breast cancer progression research. These models seem to be quite similar to 
141 
 
their donor, retaining important tumor histomorphology, imaging and gene expression 
characteristics of the donor [24-26]. Furthermore, they have been used to study predictive 
clinical outcomes with regards to drug efficacy, biomarker analysis, and patient outcomes, 
reviewed here [27], with high concordance between patients and their PDX models. 
However, there is a lack of published studies with PDX models recapitulating breast 
cancer progression from non-obligate in situ carcinomas to metastasis. Not only would 
these studies provide valuable insight into why only 1/3 of patients progress into invasive 
breast cancer they may also indicate biomarkers or factors for invasiveness. Furthermore, 
currently there are no studies revealing the transposable element or non-coding RNA 
expression profile for breast cancer PDX models.    
 
5.5 Final Thoughts 
 The idea that TEs were fundamental and continue to contribute to the evolution of 
regulating gene networks started with the pioneering work of Dr. Barbara McClintock. 
The selfish replicative nature of TEs has predisposed them to the co-option of host gene 
regulation. However, this co-option of TEs is widely seen as a double-edged sword. As 
described in Chapter 3, there is a large body of evidence for the diversity of domesticated 
TE mechanisms employed by whole organism, tissue-specific, and cellular systems.  
Contrarily, strong evidence linking aberrant TE activity to disease states, such as, cancer, 
ageing, neurological disorders, and autoimmunity is increasing. The double-edge nature 
of parasitic elements becoming integral components of many host functions presses for 
more granular experimental evidence of TE activity at the individual element level. We 
are in the gene-targeted therapy revolution. Current technologies, such as CRISPR-Cas 
systems, are becoming increasingly more accurate at genetic and RNA manipulation. As 
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technologies advance toward functionally testing non-coding and repeat regions of the 
genome, it will provide greater, much needed, insight into the roles of TEs in disease 
states. 
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